Does Ventricular Substrate Play a Role in Incident Stroke? The Atherosclerosis Risk in Communities (ARIC) Study

John A. Johnson¹, BS, Kazi T. Haq¹, PhD, Katherine J. Lutz¹, MD, Kyle K. Peters¹, MD, Kevin A. Paternostro¹, BS, Natalie E. Craig¹, BS, Nathan Stencel¹, BS, Lila Hawkinson¹, BA, Maedeh Khayyat-Kholghi¹, DO, MSc, Larisa G. Tereshchenko^{1,2}, MD, PhD.

¹Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR;

²Cardiovascular Division, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD.

Correspondence: Larisa Tereshchenko, 3181 SW Sam Jackson Park Rd; UHN62; Portland, OR, 97239. E-mail:tereshch@ohsu.edu. Phone:503-494-7400; Fax:503-494-8550.

Brief title:

Subject Codes: Electrocardiology; Epidemiology, stroke

ARIC MS # 3333 Approved on April 30, 2020.

Words: 12251

Abstract

Background—The goal of the study was to determine an association of ventricular substrate with thrombotic, cardioembolic, and hemorrhagic stroke.

Methods—Participants from the Atherosclerosis Risk in Communities study with analyzable ECGs and no history of stroke were included (n=14,479; age 54±6 y; 55% female; 24% black). Ventricular substrate was characterized by cardiac memory [spatial QRS-T angle (QRS-Ta), sum absolute QRST integral (SAIQRST), spatial ventricular gradient magnitude (SVGmag)], premature ventricular contractions (PVC) and tachycardia-dependent intermittent bundle branch block (TD-IBBB) on 12-lead ECG recorded at visits 1-5. Incident strokes were adjudicated by physician reviewers. Cox proportional hazard risk models were constructed.

Results—Over a median 24.5 y follow-up, there were 899 thrombotic, 400 cardioembolic, and 187 hemorrhagic strokes. After adjustment for cardiovascular disease (CVD) and its risk factors, atrial fibrillation / atrial substrate, and ECG-left ventricular hypertrophy, PVC (HR 1.72; 95%CI 1.02-2.92), QRS-Ta (HR 1.15; 95%CI 1.03-1.28), SAIQRST (HR 1.20; 95%CI 1.07-1.34) and time-updated SVGmag (HR 1.19; 95%CI 1.08-1.32) associated with cardioembolic stroke. After adjustment for CVD and its risk factors, PVC (HR 1.53; 95%CI 1.03-2.26), QRS-Ta (HR 1.08; 95%CI 1.01-1.16), SAIQRST (HR 1.07; 95%CI 1.01-1.14), and time-updated SVGmag (HR 1.11; 95%CI 1.04-1.19) associated with thrombotic stroke. In fully adjusted time-updated Cox model QRS-Ta (HR 1.20; 95%CI 1.04-1.38), SAI QRST (HR 1.23; 95%CI 1.06-1.43), SVGmag (HR 1.23; 95%CI 1.06-1.43) associated with hemorrhagic stroke, whereas TD-IBBB trended (HR 1.84; 95%CI 0.25-13.33).

Conclusions—PVC burden reflected by cardiac memory is associated with ischemic stroke. Transient cardiac memory (likely through TD-IBBB) precedes hemorrhagic stroke.

Key words: ECG, global electrical heterogeneity, stroke

Introduction

Stroke remains the leading cause of long-term disability and the 5th leading cause of death in the United States.¹ Despite declining stroke incidence in adults over 65 years of age², the global lifetime risk of stroke increased from 22.8% in 1990 to 24.9% in 2016.³ Large portions, approximately 90.5% of stroke risk, could be attributed to traditional cardiovascular risk factors, such as hypertension, obesity, hyperlipidemia, hyperglycemia, renal dysfunction, smoking, and sedentary lifestyle, as well as air pollution.⁴ Nevertheless, a recent genome-wide association study of stroke identified 22 previously unknown genetic loci, pointing towards additional, currently unrecognized mechanisms of stroke.⁵ The most accurate stroke risk prediction is provided by CHA₂DS₂-VASc and P₂-CHA₂DS₂VASc risk scores⁶, in persons with and without⁷ atrial fibrillation (AF). However, C-statistics for the stroke risk scores remain suboptimal (~0.6 to 0.7). Thus, it is essential to understand additional factors beyond those already accounted for in the risk assessment models.

Several studies reported an association of both premature ventricular complexes (PVCs)^{8, 9}, and left ventricular hypertrophy (LVH)¹⁰, with incident stroke. This suggests an abnormal ventricular substrate, with or without atrial myopathy, may serve as an independent risk factor. Furthermore, it was previously shown that left ventricular interstitial fibrosis is associated with interatrial conduction abnormalities, characterized by P-wave indices.¹¹ However, at present, the role of a ventricular substrate in stroke mechanisms is not entirely clear.

Global electrical heterogeneity (GEH) recently emerged as a global measure of an abnormal electrophysiological substrate in the ventricles of the heart.¹² GEH is a concept based on Wilson's spatial ventricular gradient (SVG) theory.¹³ It was mathematically demonstrated that the sum of the QRS and T vectors should theoretically be zero if depolarization and

repolarization occurred in the same manner. By measuring the SVG, one could quantify the global dispersion of activation and recovery. SVG is independent of the type of ventricular activation.^{14, 15} Therefore, it can be measured in individuals with or without AF or ventricular conduction abnormalities, enabling a broad study of ventricular substrates. An association of GEH with stroke has not been previously studied.

We conducted this study with the goal of uncovering novel mechanisms of stroke, to determine an association of ventricular substrate (quantified by GEH and traditional ECG metrics) with thrombotic, cardioembolic, or hemorrhagic stroke subtypes. We hypothesized that GEH is associated with incident stroke in the Atherosclerosis Risk in Communities (ARIC) study participants.

Methods

The ARIC Study data are available through the National Heart, Lung, and Blood Institute's Biological Specimen and Data Repository Information Coordinating Center (BioLINCC)¹⁶, the National Center of Biotechnology Information's database of Genotypes and Phenotypes (dbGaP)¹⁷, and via ARIC Coordinating Center at the University of North Carolina—Chapel Hill¹⁸. Informed consent was obtained from all study participants prior to enrollment. The study was approved by the Oregon Health & Science University Institutional Review Board.

Study population

The ARIC study enrolled 15,792 participants (age 45-64 y) between 1987 and 1989.¹⁹ In this study, we included ARIC study participants with recorded resting 12-lead ECG and measured global electrical heterogeneity (GEH)¹²; n=15,776. ECGs were recorded during visits 1-5. Visit 1 was coordinated in 1987-1989, visit 2 in 1990-1992, visit 3 in 1993-1995, visit 4 in 1996-1998,

and visit 5 in 2011-2013. We excluded participants with a prevalent stroke (defined²⁰ as previous stroke or transient ischemic attack identified by a standardized interview) that occurred before the 1st ECG GEH measurement (n=278). We further excluded those who were not white or black from all study sites, and nonwhite from Washington County and Minneapolis field centers (due to the relatively small sample size, n=101). Finally, we excluded participants with missing covariates or outcome (n=918). The final sample included 14,479 participants (Figure 1).

Exposure: Global Electrical Heterogeneity and other measures of ventricular substrate

We analyzed resting 12-lead ECGs of the first five study visits.^{12, 21-23} Ventricular substrate was characterized by novel ECG measures (GEH), by the presence of premature ventricular complexes (PVCs) on 10-second 12-lead ECG, and by traditional ECG measures [QRS duration, Bazett-corrected QTc interval, electrocardiographic left ventricular hypertrophy (ECG-LVH), bundle branch block (BBB) or interventricular conduction delay (IVCD)].

Each beat on a 10-second 12-lead ECG was manually labeled by at least two physicians or physicians-in-training investigators (JJ, KJL, KP, KAP, NC, LH, MKK, LGT) at the Oregon Health & Science University (Tereshchenko laboratory)²¹⁻²³, and PVCs were identified. We created a time-coherent median beat with identified isoelectric heart vector origin point.²⁴ A median beat was comprised of only one (dominant) type. In this study, we included three groups of median beats. Normal (N) group included median beats conducting from atria to ventricles (normal sinus, atrial paced, junctional, and ectopic atrial median beats). The ventricular (V) group included median beats with ventricular activation originating in ventricles (ventricular paced, and both atrial and ventricular paced median beats). The supraventricular (S) group included median beats of AF or atrial flutter with an atria-to-ventricle type of ventricular conduction.

GEH was measured by spatial QRS-T angle, SAI QRST, and SVG magnitude, azimuth, and elevation.²⁵ We used two approaches for measurement of SVG vectors and QRS-T angles: area-based, and peak-based.^{21, 24, 25} The open-source MATLAB (MathWorks, Natick, MA, USA) software code for GEH and the heart vector origin measurement is provided at <https://physionet.org/physiotools/geh> and <https://github.com/Tereshchenkolab/Origin>. We used previously selected sex- and race-stratified thresholds for abnormal GEH measurements¹², to comprise the GEH risk score ranging from 0 to 5 abnormal GEH metrics.

QRS duration, QTc, R_{aVL}, and S_{V3} amplitudes were measured by the 12 SL algorithm as implemented in the Magellan ECG Research Workstation V2 (GE Marquette Electronics, Milwaukee, WI). Cornell voltage was calculated as the sum of R_{aVL} and S_{V3} amplitudes. ECG-LVH was defined as a sex-adjusted Cornell product (Cornell voltage times QRS duration)²⁶ >2440 mm*ms.

BBB was identified by the Minnesota Code²⁷ (left bundle branch block code 7.1, right bundle branch block code 7.2 and 7.3, fascicular block code 7.6-7.7, bi-fascicular block code 7.8). IVCD was defined as a QRS duration above 120 ms in the absence of BBB criteria.

Tachycardia-dependent intermittent BBB (TD-IBBB) was diagnosed on a 12-lead ECG if an intermittent BBB morphology appeared on a normal sinus beat with shortened RR' interval or PAC with aberrant ventricular conduction (Supplemental Figures 1 and 2).

The outcomes: incident stroke subtypes

The follow-up procedures of ARIC study participants²⁸ have been described previously. In this study, we included the follow-up period from January 1st, 1987, to December 31st, 2018, for participants enrolled in Forsyth County, Minneapolis, and Washington County field centers. The follow-up period from January 1st, 1987, to December 31st, 2017, was included for participants

enrolled in the city of Jackson field center. Methods for the ascertainment of stroke events have been previously described.²⁹ Briefly, records for possible stroke-related hospitalizations were selected based on the International Classification of Diseases, 9th Revision (*ICD-9*) codes 430-438 until 1997, *ICD-9* codes 430-436 and *ICD-10* codes G45.X, I60.X, I61.X, I62.X, I63.X, I65.X, I66.X, and I67.X afterward. Data on fatal stroke was collected through linkage with the National Death Index. Strokes were then identified by a computer algorithm and adjudicated by physician reviewers.²⁹

In this study, we included three incident stroke subtype outcomes: a first definite or probable (1) thrombotic brain infarction (TBI), (2) non-carotid cardioembolic brain infarction (EBI), and (3) subarachnoid or intracranial brain hemorrhage (intracerebral hemorrhage, ICH). If a stroke case met the criteria for two different diagnostic categories, the following hierarchy was used: hemorrhagic above cardioembolic, above thrombotic, as previously described.²⁹ In this study, we considered multiple stroke events for the same participant. Thus, a participant could develop all three incident stroke subtype outcomes as three separate events.

Atrial fibrillation, ectopic atrial complexes, and use of anticoagulants/aspirin

Prevalent AF included AF or atrial flutter diagnosed on the 1st ECG. Incident AF included AF detected on follow-up 12-lead ECG or hospital discharge records and death certificates with *ICD-9-CM* code 427.31 or 427.32 or *ICD-10* code I48 listed in any position.^{30, 31}

Premature atrial complexes (PACs) were identified on 10-second 12-lead ECG, as described above.

The ARIC study participants were asked to bring their medications to the clinic, where ARIC staff filled out the Medication Survey Form (based partly on self-report by the participants). The

use of anticoagulant and aspirin-containing medications in the past two weeks was self-reported and validated by medication inventory at every study visit.

Measures of an atrial substrate and use of antiarrhythmic medications

The atrial substrate was characterized by the following P-wave indices: frontal P axis, P-terminal force in lead V₁ (PTF_{V1}), and PR interval duration. All P-wave indices, including amplitude and duration of the terminal negative phase (P-prime) of biphasic (positive/negative) P wave in lead V₁, were automatically measured by the 12SL algorithm (GE Marquette Electronics, Milwaukee, WI). PTF_{V1} was calculated as a product of P-prime amplitude and duration.^{32, 33}

The use of antiarrhythmic medications included in the study was self-reported and subsequently validated by medication inventory. Antiarrhythmic medications included class I, II (beta-blockers), III, IV (phenylalkylamines, and benzothiazepines calcium channel blockers), or V (digoxin) antiarrhythmic agents.

Carotid artery plaque

Carotid artery intima-media thickness was measured in three locations of the carotid arteries bilaterally; at the extracranial carotid artery 1 cm proximal to the dilatation of the carotid bulb, the carotid bifurcation 1 cm proximal to the flow divider, and the internal carotid artery 1 cm distal to the flow divider, using high-resolution B-mode ultrasound (Biosound 2000 II SA; Biosound, Indianapolis, IN), as previously described.³⁴⁻³⁶ ARIC ultrasound readers considered an atherosclerotic plaque to be present at any of the six segments if wall thickness exceeded 1.5 mm, or if there was a lumen encroachment or irregular intimal surface or image characteristics indicative of structural heterogeneity of the arterial wall.

Prevalent cardiovascular disease and common cardiovascular risk factors

The baseline prevalence of cardiovascular disease (CVD) was defined as the presence of prevalent coronary heart disease (CHD), peripheral artery disease (PAD), or heart failure (HF) at the first visit. Prevalent CHD included a self-reported physician-diagnosed heart attack, baseline ECG evidence of myocardial infarction (MI) by the Minnesota code³⁷, or a history of coronary revascularization (either via coronary artery bypass surgery or percutaneous coronary intervention). Prevalent PAD was defined as self-reported history of leg pain during walking that disappeared within 10 minutes after rest, an ankle-brachial index <0.9, or leg artery revascularization.³⁸ Prevalent HF was defined as asymptomatic (stage 3 by the Gothenburg criteria) HF, manifesting by cardiac and pulmonary symptoms, on medical treatment³⁹, or self-reported use of HF medication.

Body mass index (BMI) was calculated as weight (kg)/height (m)². Waist-to-hip ratio (WHR) was calculated as a measure of fat distribution. During the clinic visit, sitting blood pressure was measured three times, each after 5 minutes of rest. The average of the second and third of 3 consecutive measurements was used to calculate systolic and diastolic blood pressure levels. Hypertension was defined as blood pressure of $\geq 140/90$ mm Hg, or self-reported use of antihypertensive drugs. Self-reported use of antihypertensive and lipid-lowering medications in the past two weeks was validated by medication inventory at every study visit. Diabetes was defined as nonfasting blood glucose ≥ 200 mg/dL, fasting blood glucose ≥ 126 mg/dL, self-reported physician diagnosis of diabetes, or self-reported use of drugs to treat diabetes. Kidney function was assessed by estimated glomerular filtration rate (eGFR) calculated using the CKD Epidemiology Collaboration equation (CKD-EPI).⁴⁰ Physical activity was measured during leisure time, using the semicontinuous indices ranging from 1 (low) to 5 (high), defined by

modified Baecke questionnaire.⁴¹ Participants self-reported smoking and consumption of alcoholic beverages.

Statistical analyses

Continuous variables were presented as means and standard deviation (SD). We used ANOVA (for normally distributed continuous variables) and χ^2 test (for categorical variables) to compare baseline clinical characteristics in participants with 0 - 5 abnormal GEH parameters.

Analysis of circular variables

An unadjusted comparison of circular variables (spatial QRS-T angle, SVG azimuth, and SVG elevation) in participants with different types of stroke was performed using the Wheeler-Watson-Mardia test.

Because distributions of QRS-T and SVG elevation angles were normal or nearly normal, we included them in all conventional statistical analyses without transformation. The SVG azimuth angle is expressed as an axial variable, ranging from -180° to $+180^\circ$. Thus, as recommended⁴², we transformed SVG azimuth by doubling its value and then adding 360° . We then analyzed the SVG azimuth in multivariable Cox regression analysis and converted it back for interpretation.

Survival analyses

We built Cox proportional hazard risk models. All continuous ECG exposure variables were expressed as their z score to standardize comparisons. The proportional-hazards assumption was verified using *stcox* PH-assumptions suite of tests implemented in STATA (StataCorp LP, College Station, TX), and exceptions were reported. To adjust for confounders, we constructed five models with incremental adjustment. Model 1 was adjusted for demographic characteristics (age, sex, and race-study center group).

Model 2, in addition to model 1 covariates, was adjusted for prevalent at baseline CVD and risk factors (BMI, WHR, total cholesterol, HDL, triglyceride level, use of lipid-lowering medications, current smoking, consumption of alcohol, level of physical activity at leisure time, diabetes, hypertension, levels of systolic and diastolic blood pressure, use of blood pressure-lowering drugs, eGFR_{CKD-EPI}, and the presence of carotid artery plaque).

Model 3 further added characteristics of an atrial substrate [abnormal P axis (less than 0 or above 75°)⁶, abnormal PR interval (less than 120 ms or above 200 ms)³¹, abnormal PTF_{V1} ($\leq -4000 \mu V \cdot ms$)⁶], heart rate, use of antiarrhythmic drugs, anticoagulants, and aspirin. In cases of P-wave absence, PR interval and P-wave indices were categorized as abnormal. Model 3 also added presence of PACs on 10-second 12-lead ECG at any visit, S or V median beat at any visit, and presence of AF at baseline or at any time during follow-up (assuming incident AF has been present since baseline).⁴³

Model 4 adjusted for model 3 covariates plus characteristics of a ventricular substrate (QRS duration, QTc interval, presence of BBB/IVCD, ECG-LVH, categorical GEH risk score, and presence of PVCs on 10-second 12-lead ECG at any visit). Categorical GEH risk score was not included in the models with continuous GEH variables serving as predictors.

Time-updated model 5 included all model 4 covariates, as well as ECG variables that were updated at the date of ECG recording in visits 1-5, as time-updated exposure (QRS duration, QTc interval, presence of BBB/IVCD, ECG-LVH, and GEH variables), and time-updated covariates (abnormal P-axis, abnormal PTF_{V1}, abnormal PR interval, heart rate, presence of PAC and PVC on a single 10-second 12-lead ECG, and a type of median beat).

Associations of continuous ECG variables with stroke were also studied using adjusted (model 1) Cox regression models incorporating cubic splines with 4 knots.

Sensitivity analyses

To assess the robustness of the study findings, we conducted several sensitivity analyses. First, we repeated all survival analyses after excluding participants with two or three different types of stroke. Also, as statistical power for hemorrhagic stroke was less than for ischemic stroke, we constructed sequential (instead of incremental) sets of models 3-5 with hemorrhagic stroke outcome, to avoid overfitting. Model 3 included age, sex, race and study center, prevalent at baseline CVD, abnormal P axis, abnormal PR interval, abnormal PTF_{V1}, heart rate, use of antiarrhythmic drugs, anticoagulants, and aspirin, presence of PACs on 10-second 12-lead ECG at any visit, S or V median beat at any visit and presence of AF at baseline or at any time during follow-up. Model 4 adjusted for age, sex, race and study center, QRS duration, QTc interval, presence of BBB/IVCD, ECG-LVH, presence of PVCs on 10-second 12-lead ECG at any visit, and categorical GEH risk score. Categorical GEH risk score was not included in the models with continuous GEH variables serving as predictors. Time-updated model 5 included age, sex, race and study center, and ECG variables that were updated at the date of ECG recording in visits 1-5 (presence of TD-IBBB on a single 10-second 12-lead ECG, GEH variables, QRS duration, QTc interval, presence of BBB/IVCD on a single 10-second 12-lead ECG, ECG-LVH, abnormal P-axis, abnormal PTF_{V1}, abnormal PR interval, heart rate, presence of PAC and PVC on a single 10-second 12-lead ECG, and a type of median beat).

Statistical analyses were performed using STATA MP 16.1 (StataCorp LP, College Station, TX). A P value < 0.05 was considered statistically significant.

Results

Study population

More than half of the participants had 0-1 abnormal GEH measures, and only 6% had 4-5 abnormal GEH metrics (Table 1). PVCs were detected on a 12-lead ECG in 280 (1.93%) participants at baseline and 1,202 (8.30%) participants at any visit. TD-IBBB was observed in at least one ECG in 122(0.84%) participants. Participants with more abnormal GEH were more likely to have prevalent CVD and traditional cardiovascular risk factors (hypertension, diabetes), and use antiarrhythmic medications and anticoagulants. Of note, there was a gradual increase in the presence of carotid plaque and a gradual decrease in the level of HDL, consistent with a growth in the number of abnormal GEH metrics (Table 1). As expected, abnormal P wave indices, PACs, PVCs, and ventricular conduction abnormalities were more likely to be observed in participants with abnormal GEH.

Incident stroke

Over a median follow-up of 24.5 years, there were 899 thrombotic strokes (incidence 2.87; 95% CI 2.69-3.07 per 1000 person-years), 400 cardioembolic strokes (incidence 1.26; 95% CI 1.14-1.39 per 1000 person-years), and 187 hemorrhagic strokes (incidence 0.59; 95% CI 0.51-0.68 per 1000 person-years). Two participants experienced all three types of incident stroke; 62 participants suffered from both types of ischemic stroke (TBI and EBI), and another 17 participants endured both ICH and either TBI or EBI. Overall, baseline GEH was more abnormal in participants who developed any type of stroke during follow-up (Table 2).

Ventricular substrate and cardioembolic stroke

In minimally adjusted model 1, nearly all measures of the ventricular substrate (except QRS duration, SVG magnitude, and ventricular conduction abnormalities) associated with incident

cardioembolic stroke (Table 3). Model 2 showed that CVD and cardiovascular risk factors explained a significant portion of an association of QRS-T angle, SVG direction, QTc interval, and ECG-LVH with incident EBI (Figure 2). Of note, an association of SAI QRST and PVCs with cardioembolic stroke was independent of CVD and cardiovascular risk factors. Neither persistent BBB/IVCD nor TD-IBBB associated with cardioembolic stroke.

The addition of the atrial substrate metrics in model 3 resulted in further attenuation of the association of QRS-T angle and PVCs with EBI. It thoroughly explained the association of SVG direction and traditional ECG metrics (QTc, ECG-LVH) with cardioembolic stroke. Model 4 confirmed that spatial QRS-T angle, SAI QRST, and PVCs represent specific features of the ventricular substrate independently associated with EBI. Notably, the association of QRS-T angle and SAI QRST with EBI was "dose-dependent," as demonstrated by the gradually increasing risk of EBI across the distribution of QRS-T angle and SAI QRST (Figure 3). In time-updated model 5, SVG magnitude emerged as significant independent transient exposure associated with incident cardioembolic stroke (Table 3). SAI QRST and QRS-T angle remained significantly associated, too (Figure 2).

Sensitivity analysis in participants with pure EBI outcome (Table 4) strengthened observed findings, reporting higher point estimates, especially for time-dependent SVG magnitude in model 5.

Ventricular substrate and thrombotic stroke

In minimally adjusted model 1, nearly all traditional and novel measures of the ventricular substrate (except SVG elevation, magnitude, and ventricular conduction abnormalities) associated with TBI, although the strength of association was weaker for thrombotic than cardioembolic stroke (Table 3). Similar to EBI, the risk of TBI increased across the distribution

of the QRS-T angle and SAI QRST (Figure 4). Adjustment for CVD and cardiovascular risk factors in model 2 substantially attenuated the association for all ECG metrics. Spatial QRS-T angle, SAI QRST, QTc, and QRS duration, PVCs, and ECG-LVH remained associated with TBI in model 2 (Figure 5).

However, in contrast to cardioembolic stroke, further adjustment for atrial substrate in model 3 did not change the strength of associations (Table 3), suggesting that an association of a ventricular substrate with TBI was independent of atrial substrate. Again, in contrast to the cardioembolic stroke, model 4 showed that there was no independent association of GEH or other measures of the ventricular substrate with incident thrombotic stroke, as previously observed in models 1-3 associations attenuated and were not statistically significant.

Interestingly, time-updated model 5 revealed a strengthened association of SAI QRST, QT interval, and SVG magnitude with TBI, suggesting the importance of time-dependent transient ventricular substrate (Table 3).

Sensitivity analysis with pure TBI outcome demonstrated identical results, supporting the robustness of the study findings.

Ventricular substrate and hemorrhagic stroke

As ICH outcome was less frequent than ischemic stroke outcomes, resulting in a lesser statistical power, sensitivity analyses with the ICH outcome highlighted significant observations (Tables 4-5). In contrast to ischemic stroke, very few features of ventricular substrate associated with incident hemorrhagic stroke. In model 1, SVG azimuth and magnitude were associated with ICH. Still, their association was explained mainly by CVD and cardiovascular risk factors, as shown by attenuated hazard ratio estimates for SVG azimuth and magnitude in model 2 (Tables 3-4). Similar to ischemic stroke, the risk of ICH was increasing across the distribution of the

spatial area QRS-T angle and SAI QRST (Figure 6), but the strength of association was weaker and did not reach statistical significance.

Notably, the spatial peak QRS-T angle was strongly and independently associated with hemorrhagic stroke across all models (1-5), with little to no attenuation after adjustment for all confounders (Figure 7). Similar to ischemic stroke, SVG magnitude exhibited a time-dependent association with hemorrhagic stroke (Figures 8 and 9). Sensitivity analyses of pure ICH outcome highlighted and strengthened the association of time-updated SVG magnitude with ICH (Tables 4-5).

Similar to thrombotic (but not cardioembolic) stroke, adjustment for atrial substrate did not affect associations of ECG metrics with ICH, suggesting their independence from an atrial substrate. Moreover, similar to cardioembolic (but not thrombotic) stroke, adjustment for traditional ECG measures of ventricular substrate did not affect associations of GEH metrics with ICH, suggesting that they characterize specific features of the ventricular substrate.

As expected, PVCs did not associate with hemorrhagic stroke. There was a nominal association of TD-IBBB with ICH, which was consistent in a time-updated model but did not reach statistical significance (Figure 7 and Tables 4-5). It indicated a nearly two-fold higher risk of ICH in participants with TD-IBBB.

Discussion

This large, prospective, community-dwelling cohort study of more than 14 thousand adults revealed several novel findings. First, we uncovered CVD-independent ventricular substrate of cardioembolic stroke, likely reflecting the development of cardiac memory in response to idiopathic PVCs. Our results suggest that the search for the sources of cardioembolic stroke

should include an assessment of the PVC burden. Our findings open an avenue for randomized clinical trials of the ablation of idiopathic PVCs as a possible prevention strategy for a cardioembolic stroke of uncertain source.

Second, we observed a time-dependent association of a transient ventricular substrate likely reflecting cardiac memory in patients with TBI, suggesting that PVCs can also trigger a thromboembolic stroke from a brain artery. Unlike in cardioembolic stroke, PVCs that are implicated in TBI are more likely associated with CVD substrate. Future studies are needed to determine whether monitoring of cardiac memory (SVG magnitude, SAI QRST, QRS-T angle) and PVC burden in patients at risk for TBI can be useful for determining the timing of carotid endarterectomy and adjustment of the antiplatelet therapy regimen.

Finally, we found an association of CVD-independent ventricular substrate with ICH, likely reflecting the development of cardiac memory in response to TD-IBBB and suggesting an implication of amyloidosis. The TD-IBBB phenomenon and associated cardiac memory in older adults should be studied further. After validation of these study findings in another study, TD-IBBB may be used as a marker of ICH risk, increasing clinical suspicion of cardiac amyloidosis.

Notably, our study suggested that the wide spatial QRS-T angle, and the large SAI QRST and SVG magnitude are non-specific characteristics of the transient substrate of cardiac memory, developing in response to PVCs and TD-IBBB. Further ECG monitoring studies are needed to validate an association of PVC and TD-IBBB burden with the amount of cardiac memory. Monitoring of the amount of cardiac memory on 12-lead ECG can be potentially less burdensome, less expensive, and more efficient than measurement of PVCs and TD-IBBB burden by Holter ECG, or ECG-patch, and should be studied further.

The ventricular substrate of ischemic stroke

AF is a well-recognized major risk factor, and the central focus for cardioembolic stroke prevention.⁴⁴ The pathophysiological mechanisms of stroke in AF have been studied for decades.⁴⁵ However, a frequently missing temporal link between AF episodes and stroke events remains incompletely understood.^{46, 47} The atrial myopathy hypothesis⁴⁸ was developed to explain the temporal dissociation between AF and stroke, and suggests that the fibrotic atrial substrate, which interacts with the atrial electrical dysfunction⁴⁹, is the principal mediator of thromboembolism. Nevertheless, the risk of stroke is increased in a graded manner in patients with paroxysmal, persistent, and permanent AF.^{50, 51} Moreover, greater AF burden is associated with a higher risk of stroke^{52, 53}, highlighting the importance of a hemodynamic disturbance triggering thromboembolic events. Therefore, the current strategy for determining the etiology of cardioembolic stroke is to search for underlying AF.⁵⁴

Our study uncovered the presence of a CVD-independent ventricular substrate associated with cardioembolic stroke (Figure 10), which remained associated with EBI even after rigorous adjustment for CVD and cardiovascular risk factors, AF and atrial substrate^{55, 56}, and known ventricular abnormalities (BBB, LVH). PVCs and PVC burden (manifested by the cardiac memory) characterize the CVD-independent ventricular substrate of cardioembolic stroke. Several previous studies reported an association of PVCs on a 2-minute ECG recording with ischemic stroke.^{8, 9} One of these studies, Agarwal et al⁸, had smaller statistical power and did not adjust for AF and atrial substrate, however, their findings were consistent with our own. They observed that PVCs were associated with incident stroke in individuals without hypertension and diabetes, although not in those individuals with hypertension or diabetes. Previous studies^{8, 9}, also speculated that PVCs merely reflect the presence and burden of CVD. Nevertheless, our

study demonstrated that the association of PVCs with cardioembolic stroke is independent of CVD and cardiovascular risk factors (model 2, Figure 2), as well as traditional CVD-related ventricular substrate (LVH and BBB; model 4, Figure 2). Moreover, we showed that AF and atrial substrate mediate the association of PVCs with cardioembolic stroke (model 3, Figure 2).

It is well-known that PVCs can induce cardiac memory, which is manifested by a wide QRS-T angle^{57, 58}, and a large QRST integral.⁵⁹ In this study, the response of the specific ventricular substrate measures (PVCs, spatial QRS-T angle, and SAI QRST) on stepwise adjustment (models 1-4, Figure 2) was similar, supporting the notion that spatial QRS-T angle and SAI QRST reflect cardiac memory. We also observed a gradual, “dose-dependent” association of QRS-T angle and SAI QRST with the hazard of cardioembolic stroke (Figure 3).

Evidently, there are several mechanisms behind abnormal QRS-T angle⁶⁰ and SAI QRST⁶¹, which explain an attenuation of the association after adjustment for CVD and cardiovascular risk factors. Importantly, spatial QRS-T angle and SAI QRST remained associated with cardioembolic stroke after full adjustment, in time-updated model 5. This raises the possibility that cardiac memory reflects an increasing burden of PVCs before the stroke event. Moreover, we observed a strong, independent, “dose-dependent” (Figure 8) association of time-updated SVG magnitude with cardioembolic stroke. SVG magnitude reflects cardiac memory¹⁵ as a transient substrate or a trigger.²¹ As expected, the SVG direction did not associate with incident stroke because idiopathic PVCs can originate from different locations.⁶² Therefore, the results of our study suggest that the high burden of PVCs can trigger cardioembolic events. Future studies are needed to prove an association of PVC burden with cardioembolic stroke.

PVC burden can be a “missing” temporal link connecting hemodynamic disturbance due to paroxysmal arrhythmia with acute stroke events in predisposed patients (Figure 10). The ablation

of idiopathic PVCs could be an effective and safe⁶³ prophylactic measure to reduce the risk of acute stroke. Our findings open an avenue for randomized clinical trials of cardioembolic stroke prevention using the ablation of idiopathic PVCs, especially for the secondary prevention of a cardioembolic stroke of uncertain source.

Consistent with the notion that a subset of TBIs includes embolic strokes originating from a brain artery, we observed a weak association of PVCs, spatial QRS-T angle, SAI QRST, and time-updated SVG magnitude with TBI. As expected and contrary to cardioembolic stroke, the association of a ventricular substrate with TBI was independent of AF and atrial substrate. Still, the association was mediated primarily by CVD and cardiovascular risk factors, including BBB and LVH (Figure 5).

Similar to EBI, a dose-dependent association of spatial QRS-T angle, SAI QRST, and time-updated SVG magnitude with the risk of TBI (Figures 4 and 8) suggested a similar underlying mechanism - cardiac memory, reflecting PVC burden. However, unlike in cardioembolic stroke, an embolic stroke from a brain artery seems to be more likely triggered by CVD-related PVCs. Thus, monitoring of SVG magnitude (i.e., monitoring of cardiac memory due to PVC burden) in patients at risk of TBI can potentially be used to adjust antiplatelet therapy regimen or timing of carotid endarterectomy, which should be investigated further (Figure 10).

The ventricular substrate in hemorrhagic stroke

In this study, we observed CVD-independent ventricular substrate of ICH that similar to the ventricular substrates of EBI and TBI characterizes cardiac memory (wider QRS-T angle, larger SAI QRST and transient increase in SVG magnitude). However, unlike in ischemic stroke, in hemorrhagic stroke, cardiac memory is developed in response to TD-IBBB⁶⁴, suggesting the implication of amyloid (Figure 11).

Cerebral microbleeds are the strongest risk factors of hemorrhagic stroke.⁶⁵ Cerebral amyloid angiopathy is the second most common cause of hemorrhagic stroke, following hypertension (hypertensive arteriopathy).⁶⁶ The previous study demonstrated an association of ECG-LVH with ICH.³⁶ We adjusted our analyses by ECG-LVH, history of hypertension, antihypertensive treatment, and levels of systolic and diastolic blood pressure, to account for hypertensive arteriopathy as the leading cause of ICH.

The amyloid burden is independently associated with cerebral microbleeds.⁶⁷ Amyloidosis is a systemic disease. Cardiac amyloidosis is significantly underdiagnosed, partly because of a lack of suspicion and a widespread belief that it is rare.⁶⁸ Nevertheless, wild-type transthyretin (ATTRwt) cardiac amyloidosis is common in older adults⁶⁹ and HF patients with preserved ejection fraction.⁷⁰ Recently, novel diagnostic approaches⁷¹ and therapies⁷² emerged, which can improve clinical outcomes but also demonstrate complications of longer disease durations⁷³.

Previously described ECG manifestations of cardiac amyloidosis are highly variable⁷⁴ and include ECG-LVH, low voltage, and poor R wave progression.⁷⁰ Notably, one consistent characteristic feature of all types of cardiac amyloid (light chain, mutant ATTR, and ATTRwt) includes cardiac conduction abnormalities.⁷⁵ In this study, individuals with TD-IBBB had a two-fold higher risk of ICH, but the association was not statistically significant and should be validated in another independent study.

Up to 25% of patients with cerebral amyloid angiopathy are also diagnosed with AF⁷⁶, which poses a difficult dilemma and discussion about the risks and benefits of anticoagulation for stroke prevention.⁷⁷ In our study, 19 patients experienced both hemorrhagic and ischemic stroke. Our results hold a promise that in the future propensities towards ischemic and hemorrhagic

stroke can be dissected based on the presence of TD-IBBB or PVCs, and monitoring the extent of cardiac memory.

Strengths and Limitations

The strengths of our study included a large prospective cohort with long-term follow-up and well-adjudicated stroke events, providing sufficient statistical power for rigorous adjustment. However, the limitations of the study should be taken into consideration. While the statistical power for ischemic stroke was adequate, there were fewer ICH events, which challenged a fair comparison of models for ischemic and hemorrhagic stroke events. To overcome that limitation, we conducted sensitivity analysis and utilized sequential rather than an incremental adjustment in Cox regression models with ICH outcome.

In 2017, the American College of Cardiology/American Heart Association Guideline lowered the threshold for the definition of hypertension in adults (systolic blood pressure ≥ 130 or a diastolic blood pressure ≥ 80 mmHg)⁷⁸. To maintain consistency with all previous research in ARIC, we kept the historical definition of hypertension. However, we also adjusted for actual blood pressure values, considering the paramount importance of hypertension as a stroke risk factor.

Assessment of paroxysmal arrhythmic events (AF, PACs, PVCs, TD-IBBB) on a 10-second ECG cannot accurately represent the burden of arrhythmia. To minimize this limitation, we assumed that AF diagnosed at any time during follow-up, as well as PACs, PVCs, and TD-IBBB, detected at any visit have been present since baseline. Moreover, we also assessed PACs, PVCs, and TD-IBBB in time-updated models, updating their presence on the exact day of ECG recording.

Acknowledgments:

The authors thank the staff and participants of the ARIC study for their important contributions.

Funding Sources:

The Atherosclerosis Risk in Communities study has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, under Contract nos. (HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700004I, HHSN268201700005I). This work was supported by HL118277 (LGT).

Disclosures

None.

References

1. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Shay CM, Spartano NL, Stokes A, Tirschwell DL, VanWagner LB, Tsao CW, American Heart Association Council on Epidemiology, Prevention Statistics Committee, Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. *Circulation*. 2020;141:e139-e596
2. Koton S, Sang Y, Schneider ALC, Rosamond WD, Gottesman RF, Coresh J. Trends in Stroke Incidence Rates in Older US Adults: An Update From the Atherosclerosis Risk in Communities (ARIC) Cohort Study. *JAMA Neurol*. 2019;10.1001/jamaneurol.2019.3258
3. Global, Regional, and Country-Specific Lifetime Risks of Stroke, 1990 and 2016. *New England Journal of Medicine*. 2018;379:2429-2437
4. Feigin VL, Roth GA, Naghavi M, Parmar P, Krishnamurthi R, Chugh S, Mensah GA, Norrving B, Shiue I, Ng M, Estep K, Cercy K, Murray CJL, Forouzanfar MH. Global burden of stroke and risk factors in 188 countries, during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. *The Lancet Neurology*. 2016;15:913-924
5. Malik R, Chauhan G, Traylor M, Sargurupremraj M, Okada Y, Mishra A, Rutten-Jacobs L, Giese AK, van der Laan SW, Gretarsdottir S, Anderson CD, Chong M, Adams HHH, Ago T, Almgren P, Amouyel P, Ay H, Bartz TM, Benavente OR, Bevan S, Boncoraglio GB, Brown RD, Jr., Butterworth AS, Carrera C, Carty CL, Chasman DI, Chen WM, Cole JW, Correa A,

Cotlarciuc I, Cruchaga C, Danesh J, de Bakker PIW, DeStefano AL, den Hoed M, Duan Q, Engelter ST, Falcone GJ, Gottesman RF, Grewal RP, Gudnason V, Gustafsson S, Haessler J, Harris TB, Hassan A, Havulinna AS, Heckbert SR, Holliday EG, Howard G, Hsu FC, Hyacinth HI, Ikram MA, Ingelsson E, Irvin MR, Jian X, Jimenez-Conde J, Johnson JA, Jukema JW, Kanai M, Keene KL, Kissela BM, Kleindorfer DO, Kooperberg C, Kubo M, Lange LA, Langeveld CD, Langenberg C, Launer LJ, Lee JM, Lemmens R, Leys D, Lewis CM, Lin WY, Lindgren AG, Lorentzen E, Magnusson PK, Maguire J, Manichaikul A, McArdle PF, Meschia JF, Mitchell BD, Mosley TH, Nalls MA, Ninomiya T, O'Donnell MJ, Psaty BM, Pulit SL, Rannikmae K, Reiner AP, Rexrode KM, Rice K, Rich SS, Ridker PM, Rost NS, Rothwell PM, Rotter JI, Rundek T, Sacco RL, Sakaue S, Sale MM, Salomaa V, Sapkota BR, Schmidt R, Schmidt CO, Schminke U, Sharma P, Slowik A, Sudlow CLM, Tanislav C, Tatlisumak T, Taylor KD, Thijs VNS, Thorleifsson G, Thorsteinsdottir U, Tiedt S, Trompet S, Tzourio C, van Duijn CM, Walters M, Wareham NJ, Wassertheil-Smoller S, Wilson JG, Wiggins KL, Yang Q, Yusuf S, Bis JC, Pastinen T, Ruusalepp A, Schadt EE, Koplev S, Bjorkegren JLM, Codoni V, Civelek M, Smith NL, Tregouet DA, Christophersen IE, Roselli C, Lubitz SA, Ellinor PT, Tai ES, Kooner JS, Kato N, He J, van der Harst P, Elliott P, Chambers JC, Takeuchi F, Johnson AD, Sanghera DK, Melander O, Jern C, Strbian D, Fernandez-Cadenas I, Longstreth WT, Jr., Rolfs A, Hata J, Woo D, Rosand J, Pare G, Hopewell JC, Saleheen D, Stefansson K, Worrall BB, Kittner SJ, Seshadri S, Fornage M, Markus HS, Howson JMM, Kamatani Y, Debette S, Dichgans M. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. *Nature genetics*. 2018;50:524-537

6. Maheshwari A, Norby FL, Roetker NS, Soliman EZ, Koene RJ, Rooney MR, O'Neal WT, Shah AM, Claggett BL, Solomon SD, Alonso A, Gottesman RF, Heckbert SR, Chen LY. Refining Prediction of Atrial Fibrillation-Related Stroke Using the P2-CHA2DS2-VASc Score. *Circulation*. 2019;139:180-191
7. Koene RJ, Alraies MC, Norby FL, Soliman EZ, Maheshwari A, Lip GYH, Alonso A, Chen LY. Relation of the CHA2DS2-VASc Score to Risk of Thrombotic and Embolic Stroke in Community-Dwelling Individuals Without Atrial Fibrillation (From The Atherosclerosis Risk in Communities [ARIC] Study). *Am J Cardiol*. 2019;123:402-408
8. Agarwal SK, Heiss G, Rautaharju PM, Shahar E, Massing MW, Simpson RJ, Jr. Premature ventricular complexes and the risk of incident stroke: the Atherosclerosis Risk In Communities (ARIC) Study. *Stroke*. 2010;41:588-593
9. Ofoma U, He F, Shaffer ML, Naccarelli GV, Liao D. Premature cardiac contractions and risk of incident ischemic stroke. *J Am Heart Assoc*. 2012;1:e002519
10. Pirinen J, Eranti A, Knekt P, Lehto M, Martinez-Majander N, Aro AL, Rissanen H, Heliovaara M, Kaste M, Tatlisumak T, Huikuri H, Putaala J. ECG markers associated with ischemic stroke at young age - a case-control study. *Ann Med*. 2017;49:562-568
11. Tiffany Win T, Ambale Venkatesh B, Volpe GJ, Mewton N, Rizzi P, Sharma RK, Strauss DG, Lima JA, Tereshchenko LG. Associations of electrocardiographic P-wave characteristics with left atrial function, and diffuse left ventricular fibrosis defined by cardiac magnetic resonance: The PRIMERI Study. *Heart Rhythm*. 2015;12:155-162
12. Waks JW, Sitlani CM, Soliman EZ, Kabir M, Ghafoori E, Biggs ML, Henrikson CA, Sotoodehnia N, Biering-Sorensen T, Agarwal SK, Siscovick DS, Post WS, Solomon SD, Buxton AE, Josephson ME, Tereshchenko LG. Global Electric Heterogeneity Risk Score for

- Prediction of Sudden Cardiac Death in the General Population: The Atherosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies. *Circulation*. 2016;133:2222-2234
13. Waks JW, Tereshchenko LG. Global electrical heterogeneity: A review of the spatial ventricular gradient. *J Electrocardiol*. 2016;49:824-830
 14. Tereshchenko LG, Ghanem RN, Abeyratne A, Swerdlow CD. Intracardiac QT integral on far-field ICD electrogram predicts sustained ventricular tachyarrhythmias in ICD patients. *Heart Rhythm*. 2011;8:1889-1894
 15. Haq K, Cao J, Tereshchenko LG. Characteristics of Cardiac Memory in Patients with Implanted Cardioverter Defibrillator: the CAMI study. *medRxiv*. 2019;10.1101/19005181:19005181
 16. Coady SA, Mensah GA, Wagner EL, Goldfarb ME, Hitchcock DM, Giffen CA. Use of the National Heart, Lung, and Blood Institute Data Repository. *N Engl J Med*. 2017;376:1849-1858
 17. Tryka KA, Hao L, Sturcke A, Jin Y, Wang ZY, Ziyabari L, Lee M, Popova N, Sharopova N, Kimura M, Feolo M. NCBI's Database of Genotypes and Phenotypes: dbGaP. *Nucleic Acids Res*. 2014;42:D975-979
 18. ARIC. Study Description. 1987. Available at: <http://www2.csc.unc.edu/aric/distribution-agreements>. Accessed June 22nd, 2018.
 19. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. *Am J Epidemiol*. 1989;129:687-702
 20. Chambless LE, Shahar E, Sharrett AR, Heiss G, Wijnberg L, Paton CC, Sorlie P, Toole JF. Association of transient ischemic attack/stroke symptoms assessed by standardized

- questionnaire and algorithm with cerebrovascular risk factors and carotid artery wall thickness. The ARIC Study, 1987-1989. *Am J Epidemiol.* 1996;144:857-866
21. Perez-Alday EA, Bender A, German D, Mukundan SV, Hamilton C, Thomas JA, Li-Pershing Y, Tereshchenko LG. Dynamic predictive accuracy of electrocardiographic biomarkers of sudden cardiac death within a survival framework: the Atherosclerosis Risk in Communities (ARIC) study. *BMC cardiovascular disorders.* 2019;19:255
 22. Jensen K, Howell SJ, Phan F, Khayyat-Kholghi M, Wang L, Haq KT, Johnson J, Tereshchenko LG. Bringing Critical Race Praxis Into the Study of Electrophysiological Substrate of Sudden Cardiac Death: The ARIC Study. *J Am Heart Assoc.* 2020;9:e015012
 23. Howell SJ, German D, Bender A, Phan F, Mukundan SV, Perez-Alday EA, Rogovoy NM, Haq K, Yang K, Wirth A, Jensen K, Tereshchenko LG. Does Sex Modify an Association of Electrophysiological Substrate with Sudden Cardiac Death? The Atherosclerosis Risk in Communities (ARIC) Study. *bioRxiv.* 2019;10.1101/674689:674689
 24. Perez-Alday EA, Li-Pershing Y, Bender A, Hamilton C, Thomas JA, Johnson K, Lee TL, Gonzales R, Li A, Newton K, Tereshchenko LG. Importance of the heart vector origin point definition for an ECG analysis: The Atherosclerosis Risk in Communities (ARIC) study. *Comput Biol Med.* 2019;104:127-138
 25. Thomas JA, E AP-A, Junell A, Newton K, Hamilton C, Li-Pershing Y, German D, Bender A, Tereshchenko LG. Vectorcardiogram in athletes: The Sun Valley Ski Study. *Ann Noninvasive Electrocardiol.* 2019;24:e12614
 26. Okin PM, Roman MJ, Devereux RB, Borer JS, Kligfield P. Electrocardiographic diagnosis of left ventricular hypertrophy by the time-voltage integral of the QRS complex. *J Am Coll. Cardiol.* 1994;23:133-140

27. Prineas RJ, Crow RS, Zhang Z-M. *The Minnesota code manual of electrocardiographic findings : standards and procedures for measurement and classification*. London: Springer; 2010.
28. White AD, Folsom AR, Chambless LE, Sharret AR, Yang K, Conwill D, Higgins M, Williams OD, Tyroler HA. Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: methods and initial two years' experience. *Journal of clinical epidemiology*. 1996;49:223-233
29. Rosamond WD, Folsom AR, Chambless LE, Wang CH, McGovern PG, Howard G, Copper LS, Shahar E. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. *Stroke*. 1999;30:736-743
30. Alonso A, Agarwal SK, Soliman EZ, Ambrose M, Chamberlain AM, Prineas RJ, Folsom AR. Incidence of atrial fibrillation in whites and African-Americans: the Atherosclerosis Risk in Communities (ARIC) study. *Am Heart J*. 2009;158:111-117
31. Soliman EZ, Prineas RJ, Case LD, Zhang Z-m, Goff DC. Ethnic Distribution of ECG Predictors of Atrial Fibrillation and Its Impact on Understanding the Ethnic Distribution of Ischemic Stroke in the Atherosclerosis Risk in Communities (ARIC) Study. *Stroke*. 2009;40:1204-1211
32. Tereshchenko LG, Henrikson CA, Sotoodehnia N, Arking DE, Agarwal SK, Siscovick DS, Post WS, Solomon SD, Coresh J, Josephson ME, Soliman EZ. Electrocardiographic deep terminal negativity of the P wave in V(1) and risk of sudden cardiac death: the Atherosclerosis Risk in Communities (ARIC) study. *J Am Heart Assoc*. 2014;3:e001387

33. Tereshchenko LG, Shah AJ, Li Y, Soliman EZ. Electrocardiographic deep terminal negativity of the P wave in V1 and risk of mortality: the National Health and Nutrition Examination Survey III. *J Cardiovasc Electrophysiol*. 2014;25:1242-1248
34. High-resolution B-mode ultrasound scanning methods in the Atherosclerosis Risk in Communities Study (ARIC). The ARIC Study Group. *J Neuroimaging*. 1991;1:68-73
35. Ohira T, Shahar E, Chambless LE, Rosamond WD, Mosley TH, Jr., Folsom AR. Risk factors for ischemic stroke subtypes: the Atherosclerosis Risk in Communities study. *Stroke*. 2006;37:2493-2498
36. Folsom AR, Yatsuya H, Psaty BM, Shahar E, Longstreth WT. Carotid Intima-Media Thickness, Electrocardiographic Left Ventricular Hypertrophy, and Incidence of Intracerebral Hemorrhage. *Stroke*. 2011;42:3075-3079
37. Blackburn H, Keys A, Simonson E, Rautaharju P, Punsar S. The electrocardiogram in population studies. A classification system. *Circulation*. 1960;21:1160-1175
38. Hicks CW, Yang C, Ndumele CE, Folsom AR, Heiss G, Black JH, 3rd, Selvin E, Matsushita K. Associations of Obesity With Incident Hospitalization Related to Peripheral Artery Disease and Critical Limb Ischemia in the ARIC Study. *Journal of the American Heart Association*. 2018;7:e008644-e008644
39. Eriksson H, Caidahl K, Larsson B, Ohlson LO, Welin L, Wilhelmsen L, Svardsudd K. Cardiac and pulmonary causes of dyspnoea--validation of a scoring test for clinical-epidemiological use: the Study of Men Born in 1913. *Eur Heart J*. 1987;8:1007-1014
40. Matsushita K, Selvin E, Bash LD, Astor BC, Coresh J. Risk implications of the new CKD Epidemiology Collaboration (CKD-EPI) equation compared with the MDRD Study equation

for estimated GFR: the Atherosclerosis Risk in Communities (ARIC) Study. *Am J Kidney Dis.* 2010;55:648-659

41. Richardson MT, Ainsworth BE, Wu HC, Jacobs DR, Jr., Leon AS. Ability of the Atherosclerosis Risk in Communities (ARIC)/Baecke Questionnaire to assess leisure-time physical activity. *Int J Epidemiol.* 1995;24:685-693
42. Cox NJ. Speaking Stata: In Praise of Trigonometric Predictors. *The Stata Journal.* 2006;6:561-579
43. O'Neal WT, Kamel H, Zhang ZM, Chen LY, Alonso A, Soliman EZ. Advanced interatrial block and ischemic stroke: The Atherosclerosis Risk in Communities Study. *Neurology.* 2016;87:352-356
44. Tereshchenko LG, Henrikson CA, Cigarroa J, Steinberg JS. Comparative Effectiveness of Interventions for Stroke Prevention in Atrial Fibrillation: A Network Meta-Analysis. *Journal of the American Heart Association.* 2016;5
45. Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. *Lancet.* 2009;373:155-166
46. Brambatti M, Connolly SJ, Gold MR, Morillo CA, Capucci A, Muto C, Lau CP, Van Gelder IC, Hohnloser SH, Carlson M, Fain E, Nakamya J, Mairesse GH, Halytska M, Deng WQ, Israel CW, Healey JS, ASSERT Investigators. Temporal relationship between subclinical atrial fibrillation and embolic events. *Circulation.* 2014;129:2094-2099
47. Camen S, Ojeda FM, Niiranen T, Gianfagna F, Vishram-Nielsen JK, Costanzo S, Soderberg S, Vartiainen E, Donati MB, Lochen ML, Pasterkamp G, Magnussen C, Kee F, Jousilahti P, Hughes M, Kontto J, Mathiesen EB, Koenig W, Palosaari T, Blankenberg S, de Gaetano G, Jorgensen T, Zeller T, Kuulasmaa K, Linneberg A, Salomaa V, Iacoviello L, Schnabel RB.

Temporal relations between atrial fibrillation and ischaemic stroke and their prognostic impact on mortality. *Europace*. 2020;22:522-529

48. Calenda BW, Fuster V, Halperin JL, Granger CB. Stroke risk assessment in atrial fibrillation: risk factors and markers of atrial myopathy. *Nat Rev Cardiol*. 2016;13:549-559
49. German DM, Kabir MM, Dewland TA, Henrikson CA, Tereshchenko LG. Atrial Fibrillation Predictors: Importance of the Electrocardiogram. *Ann Noninvasive Electrocardiol*. 2016;21:20-29
50. Ganesan AN, Chew DP, Hartshorne T, Selvanayagam JB, Aylward PE, Sanders P, McGavigan AD. The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis. *Eur Heart J*. 2016;37:1591-1602
51. Vanassche T, Lauw MN, Eikelboom JW, Healey JS, Hart RG, Alings M, Avezum A, Diaz R, Hohnloser SH, Lewis BS, Shestakovska O, Wang J, Connolly SJ. Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. *Eur Heart J*. 2015;36:281-287a
52. Boriani G, Glotzer TV, Santini M, West TM, De Melis M, Sepsi M, Gasparini M, Lewalter T, Camm JA, Singer DE. Device-detected atrial fibrillation and risk for stroke: an analysis of >10,000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices). *Eur Heart J*. 2014;35:508-516
53. Turakhia MP, Ziegler PD, Schmitt SK, Chang Y, Fan J, Than CT, Keung EK, Singer DE. Atrial Fibrillation Burden and Short-Term Risk of Stroke: Case-Crossover Analysis of Continuously Recorded Heart Rhythm From Cardiac Electronic Implanted Devices. *Circ Arrhythm Electrophysiol*. 2015;8:1040-1047

54. Schnabel RB, Haeusler KG, Healey JS, Freedman B, Boriani G, Brachmann J, Brandes A, Bustamante A, Casadei B, Crijns H, Doehner W, Engstrom G, Fauchier L, Friberg L, Gladstone DJ, Glotzer TV, Goto S, Hankey GJ, Harbison JA, Hobbs FDR, Johnson LSB, Kamel H, Kirchhof P, Korompoki E, Krieger DW, Lip GYH, Lochen ML, Mairesse GH, Montaner J, Neubeck L, Ntaios G, Piccini JP, Potpara TS, Quinn TJ, Reiffel JA, Ribeiro ALP, Rienstra M, Rosenqvist M, Themistoclakis S, Sinner MF, Svendsen JH, Van Gelder IC, Wachter R, Wijeratne T, Yan B. Searching for Atrial Fibrillation Poststroke: A White Paper of the AF-SCREEN International Collaboration. *Circulation*. 2019;140:1834-1850
55. Murthy S, Rizzi P, Mewton N, Strauss DG, Liu CY, Volpe GJ, Marchlinski FE, Spooner P, Berger RD, Kellman P, Lima JAC, Tereshchenko LG. Number of P- Wave Fragmentations on P- SAECG Correlates with Infiltrated Atrial Fat. *Annals of Noninvasive Electrocardiology*. 2014;19:114-121
56. Tereshchenko LG, Rizzi P, Mewton N, Volpe GJ, Murthy S, Strauss DG, Liu CY, Marchlinski FE, Spooner P, Berger RD, Kellman P, Lima JA. Infiltrated atrial fat characterizes underlying atrial fibrillation substrate in patients at risk as defined by the ARIC atrial fibrillation risk score. *Int J Cardiol*. 2014;172:196-201
57. Shvilkin A, Bojovic B, Vajdic B, Gussak I, Zimetbaum P, Josephson ME. Vectorcardiographic determinants of cardiac memory during normal ventricular activation and continuous ventricular pacing. *Heart Rhythm*. 2009;6:943-948
58. Shvilkin A, Huang HD, Josephson ME. Cardiac memory: diagnostic tool in the making. *Circ Arrhythm Electrophysiol*. 2015;8:475-482
59. Sakamoto Y, Inden Y, Okamoto H, Mamiya K, Tomomatsu T, Fujii A, Yanagisawa S, Shibata R, Hirai M, Murohara T. T-wave changes of cardiac memory caused by frequent

- premature ventricular contractions originating from the right ventricular outflow tract. *J Cardiovasc Electrophysiol*. 2019;30:1549-1556
60. Oehler A, Feldman T, Henrikson CA, Tereshchenko LG. QRS-T Angle: A Review. *Ann Noninvasive Electrocardiol*. 2014;19:534-542
 61. Tereshchenko LG, Sotoodehnia N, Sitlani CM, Ashar FN, Kabir M, Biggs ML, Morley MP, Waks JW, Soliman EZ, Buxton AE, Biering-Sorensen T, Solomon SD, Post WS, Cappola TP, Siscovick DS, Arking DE. Genome-Wide Associations of Global Electrical Heterogeneity ECG Phenotype: The ARIC (Atherosclerosis Risk in Communities) Study and CHS (Cardiovascular Health Study). *J Am Heart Assoc*. 2018;7:e008160
 62. Josephson ME, Callans DJ. Using the twelve-lead electrocardiogram to localize the site of origin of ventricular tachycardia. *Heart Rhythm*. 2005;2:443-446
 63. de Vries LJ, Hendriks AA, Yap SC, Theuns DAMJ, van Domburg RT, Szili-Torok T. Procedural and long-term outcome after catheter ablation of idiopathic outflow tract ventricular arrhythmias: comparing manual, contact force, and magnetic navigated ablation. *EP Europace*. 2018;20:ii22-ii27
 64. Seibolt L, Maestas C, Lazkani M, Fatima U, Loli A, Chesser M. Rate-related left bundle branch block and cardiac memory in a patient with bradycardia: Case report and literature review. *Clin Cardiol*. 2018;41:1097-1102
 65. Akoudad S, Portegies ML, Koudstaal PJ, Hofman A, van der Lugt A, Ikram MA, Vernooij MW. Cerebral Microbleeds Are Associated With an Increased Risk of Stroke: The Rotterdam Study. *Circulation*. 2015;132:509-516
 66. Yamada M. Cerebral amyloid angiopathy: emerging concepts. *J Stroke*. 2015;17:17-30

67. Graff-Radford J, Botha H, Rabinstein AA, Gunter JL, Przybelski SA, Lesnick T, Huston J, 3rd, Flemming KD, Preboske GM, Senjem ML, Brown RD, Jr., Mielke MM, Roberts RO, Lowe VJ, Knopman DS, Petersen RC, Kremers W, Vemuri P, Jack CR, Jr., Kantarci K. Cerebral microbleeds: Prevalence and relationship to amyloid burden. *Neurology*. 2019;92:e253-e262
68. Alexander KM, Orav J, Singh A, Jacob SA, Menon A, Padera RF, Kijewski MF, Liao R, Di Carli MF, Laubach JP, Falk RH, Dorbala S. Geographic Disparities in Reported US Amyloidosis Mortality From 1979 to 2015: Potential Underdetection of Cardiac Amyloidosis. *JAMA Cardiol*. 2018;3:865-870
69. Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J, Singleton A, Kiuru-Enari S, Paetau A, Tienari PJ, Myllykangas L. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. *Ann Med*. 2008;40:232-239
70. Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, Bornstein B, Salas C, Lara-Pezzi E, Alonso-Pulpon L, Garcia-Pavia P. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. *Eur Heart J*. 2015;36:2585-2594
71. Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, Wechalekar AD, Berk JL, Quarta CC, Grogan M, Lachmann HJ, Bokhari S, Castano A, Dorbala S, Johnson GB, Glaudemans AWJM, Rezk T, Fontana M, Palladini G, Milani P, Guidalotti PL, Flatman K, Lane T, Vonberg FW, Whelan CJ, Moon JC, Ruberg FL, Miller EJ, Hutt DF, Hazenberg BP, Rapezzi C, Hawkins PN. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. *Circulation*. 2016;133:2404-2412

72. Alexander KM, Singh A, Falk RH. Novel pharmacotherapies for cardiac amyloidosis. *Pharmacol Ther.* 2017;180:129-138
73. Sekijima Y, Yazaki M, Oguchi K, Ezawa N, Yoshinaga T, Yamada M, Yahikozawa H, Watanabe M, Kametani F, Ikeda S. Cerebral amyloid angiopathy in posttransplant patients with hereditary ATTR amyloidosis. *Neurology.* 2016;87:773-781
74. Cyrille NB, Goldsmith J, Alvarez J, Maurer MS. Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis. *Am J Cardiol.* 2014;114:1089-1093
75. Giancaterino S, Urey MA, Darden D, Hsu JC. Management of Arrhythmias in Cardiac Amyloidosis. *JACC: Clinical Electrophysiology.* 2020;6:351-361
76. Kaiser J, Schebesch KM, Brawanski A, Linker RA, Schlachetzki F, Wagner A. Long-Term Follow-Up of Cerebral Amyloid Angiopathy-Associated Intracranial Hemorrhage Reveals a High Prevalence of Atrial Fibrillation. *J Stroke Cerebrovasc Dis.* 2019;28:104342
77. Charidimou A, Shoamanesh A, Al-Shahi Salman R, Cordonnier C, Perry LA, Sheth KN, Biffi A, Rosand J, Viswanathan A. Cerebral amyloid angiopathy, cerebral microbleeds and implications for anticoagulation decisions: The need for a balanced approach. *Int J Stroke.* 2018;13:117-120
78. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Himmelfarb CD, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbigele B, Smith SC, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA, Williamson JD, Wright JT. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in

Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Hypertension*. 2018;71:e13-e115

Table 1. Comparison of baseline clinical and ECG characteristics in participants with abnormal GEH measurements

Characteristics	Normal GEH (n=2,837; 19.5%)	1 abnormal GEH (n=5,290; 36.6%)	2 abnormal GEH (n=4,090; 28%)	3 abnormal GEH (n=1,382; 10%)	4 abnormal GEH (n=555; 4%)	5 abnormal GEH (n=325; 2%)	ANOVA or χ^2 <i>P</i>
Age(SD), y	53.4(5.7)	54.0(5.7)	54.3(5.8)	54.8(5.8)	55.1(5.8)	56.8(5.6)	<0.0001
Female, n(%)	2,777(97.9)	2,872(54.3)	1,598(39.1)	527(38.1)	113(20.4)	117(36.0)	<0.0001
White, n(%)	2,189(77.2)	4,075(77.0)	3,159(77.2)	979(70.8)	340(61.3)	193(59.4)	<0.0001
Prevalent cardiovascular disease, n(%)	291(10.3)	572(10.8)	503(12.3)	235(17.0)	126(22.7)	107(32.9)	<0.0001
Body mass index(SD), kg/m ²	27.7(5.6)	27.8(5.3)	27.4(5.0)	27.3(5.2)	26.9(4.6)	27.7(4.9)	0.0001
Waist-to-hip ratio (SD)	0.896(0.081)	0.929(0.077)	0.934(0.075)	0.934(0.077)	0.943(0.069)	0.940(0.070)	<0.0001
Hypertension, n(%)	739(26.1)	1,709(32.3)	1,391(34.0)	569(41.2)	281(50.6)	176(54.2)	<0.0001
Antihypertensive drugs, n(%)	750(26.4)	1,525(28.8)	1,153(28.2)	484(35.0)	230(41.4)	145(44.6)	<0.0001
Systolic blood pressure(SD), mmHg	116.4(16.5)	120.2(17.6)	121.8(18.3)	124.9(20.0)	129.8(24.7)	129.8(23.4)	<0.0001
Diastolic blood pressure(SD), mmHg	70.8(9.9)	73.4(10.6)	74.0(10.8)	74.9(12.4)	78.0(14.6)	77.8(14.7)	<0.0001
eGFR _{CKD-EPI} (SD), mL/min/1.73 m ²	96.9(14.3)	95.7(15.1)	95.3(14.9)	94.4(16.3)	94.4(17.3)	90.2(18.8)	<0.0001
Diabetes, n(%)	247(8.7)	556(10.5)	477(11.7)	195(14.1)	98(17.7)	64(19.7)	<0.0001
Current tobacco smoker, n(%)	647(22.8)	1,315(24.9)	1,071(26.2)	426(30.8)	186(33.5)	85(26.2)	<0.0001
Current alcohol drinker, n(%)	1,519(53.5)	3,044(57.5)	2,390(58.4)	780(56.4)	313(56.4)	170(52.3)	0.001
Leisure physical activity score(SD)	2.42(0.58)	2.37(0.57)	2.37(0.56)	2.33(0.58)	2.27(0.57)	2.27(0.56)	<0.0001
Total cholesterol(SD), mmol/L	5.66(1.09)	5.54(1.08)	5.50(1.06)	5.51(1.05)	5.55(1.11)	5.53(1.07)	<0.0001
HDL cholesterol(SD), mg/dL	57.2(16.7)	51.3(17.2)	49.8(16.7)	49.7(17.0)	48.3(17.1)	23.2(25.7)	<0.0001
Triglycerides(SD), mmol/L	1.39(0.97)	1.50(1.00)	1.50(1.03)	1.53(1.07)	1.53(1.00)	1.55(1.01)	<0.0001
Lipid-lowering drugs, n(%)	78(2.8)	148(2.8)	123(3.0)	46(3.3)	17(3.1)	15(4.6)	0.448
Plaque in any carotid site, n(%)	688(24.3)	1,701(32.2)	1,435(35.1)	533(38.6)	243(43.8)	152(46.8)	<0.0001
Aspirin, n(%)	1,389(49.0)	2,466(46.6)	1,905(46.6)	637(46.1)	234(42.2)	147(45.2)	0.054
Anticoagulants, n(%)	2(0.07)	12(0.23)	16(0.39)	11(0.80)	7(1.26)	9(2.77)	<0.0001
Antiarrhythmic drugs, n(%)	293(10.3)	668(12.6)	566(13.8)	253(18.3)	132(23.8)	79(24.3)	<0.0001
Heart rate(SD), bpm	67.7(9.6)	66.1(9.9)	65.2(10.3)	66.3(11.4)	65.5(10.6)	67.3(11.0)	<0.0001
QRS duration(SD), ms	85.7(7.8)	90.4(9.5)	93.8(10.5)	98.7(14.9)	107.7(20.2)	106.5(25.5)	<0.0001
Bazett-corrected QTc(SD), ms	417.8(18.3)	414.7(18.1)	414.3(17.8)	418.2(20.2)	423.1(24.3)	428.3(31.7)	<0.0001
ECG-LVH, n(%)	16(0.6)	109(2.1)	170(4.2)	197(14.3)	195(35.1)	119(36.6)	<0.0001
BBB/IVCD, n(%)	30(1.1)	111(2.1)	146(3.6)	138(10.0)	123(22.2)	60(18.5)	<0.0001

Any visit TD-IBBB, n(%)	16(0.56)	54(1.02)	37(0.90)	9(0.65)	2(0.36)	4(1.23)	0.181
Any visit PVC, n(%)	152(5.4)	402(7.6)	388(9.5)	166(12.0)	61(11.0)	33(10.2)	<0.0001
Any visit PAC, n(%)	202(7.1)	460(8.7)	361(8.8)	129(9.3)	44(7.9)	29(8.9)	0.097
Any visit Atrial Fibrillation, n(%)	472(16.6)	1,136(21.5)	897(21.9)	357(25.8)	128(23.1)	47(14.5)	<0.0001
Abnormal PR interval, n(%)	219(7.7)	447(8.5)	367(9.0)	142(10.3)	80(14.4)	47(14.5)	<0.0001
Abnormal Frontal P axis, n(%)	188(6.6)	399(7.5)	345(8.4)	152(11.0)	67(12.1)	37(11.4)	<0.0001
Abnormal PTF in V1, n(%)	171(6.0)	439(8.3)	440(10.8)	217(15.7)	119(21.4)	60(18.5)	<0.0001
Median beat S or V at any visit, n(%)	44(1.6)	140(2.7)	134(3.3)	63(4.6)	24(4.3)	16(4.9)	<0.0001

HDL=High-density lipoprotein; SD=standard deviation

Table 2. GEH in participants with different types of stroke

Characteristics	No stroke (n=13,076)	Only TS (n=819)	Only ES (n=335)	Only HS (n=168)	TS & ES (n=62)	HS & TS/ES (n=19)	P-value
Heart rate(SD), bpm	66.1(10.1)	66.9(10.9)	66.4(10.9)	66.0(10.9)	67.8(10.6)	67.6(5.9)	0.282
QRS duration(SD), ms	92.2(12.4)	93.8(13.8)	93.0(11.1)	90.7(11.1)	91.1(11.5)	91.4(11.8)	0.004
Bazett QTc(SD), ms	415.9(19.0)	418.8(20.5)	418.5(19.1)	417.4(20.3)	418.4(16.6)	416.4(19.2)	0.0002
ECG-LVH, n(%)	674(5.2)	79(9.7)	34(10.2)	13(7.7)	3(4.8)	3(15.8)	<0.0001
PVC any visit, n(%)	1,049(8.0)	87(10.6)	53(15.8)	8(4.8)	4(6.5)	1(5.3)	<0.0001
BBB/IVCD, n(%)	541(4.1)	42(5.1)	15(4.5)	7(4.2)	2(3.2)	1(5.3)	0.829
TD-IBBB any visit, n(%)	109(0.83)	7(0.85)	2(0.60)	3(1.79)	1(1.61)	0(0)	0.754
Atrial fibrillation any visit, n(%)	2,549(19.5)	183(22.3)	233(70.0)	29(17.3)	38(61.3)	5(26.3)	<0.0001
PAC any visit, n(%)	1,079(8.3)	82(10.0)	43(12.8)	15(8.9)	5(8.1)	1(5.3)	0.037
Median beat S or V at any visit, n(%)	352(2.7)	14(1.7)	47(14.0)	2(1.2)	5(8.1)	1(5.3)	<0.0001
Abnormal PR interval, n(%)	1,159(8.9)	82(10.0)	40(11.9)	11(6.6)	9(14.5)	1(5.3)	0.121
Abnormal Frontal P axis, n(%)	1,065(8.1)	76(9.3)	27(8.1)	11(6.6)	6(9.7)	3(15.8)	0.613
Abnormal PTF in V1, n(%)	1,240(9.5)	125(15.3)	47(14.0)	19(11.3)	9(14.5)	6(31.6)	<0.0001
Peak QRS-T angle(circular 95%CI), °	41.5(41.0-42.0)	46.4(44.3-48.6)	49.0(45.3-52.7)	48.0(43.1-52.9)	47.7(38.8-56.6)	56.9(35.4-78.5)	<0.0001
Area QRS-T angle(circular 95%CI), °	60.0(59.6-60.5)	63.8(61.7-65.9)	65.3(62.0-68.6)	61.9(57.7-66.2)	65.0(57.9-72.1)	69.3(52.7-85.9)	0.442
Peak SVG elevation(circular SD), °	63.1(62.9-63.4)	64.9(63.9-66.0)	66.2(64.5-67.9)	63.3(61.0-65.5)	66.5(62.8-70.2)	66.7(58.0-75.4)	0.006
Area SVG elevation(circular SD), °	67.2(66.9-67.5)	69.2(68.0-70.4)	70.0(68.0-72.0)	67.7(65.3-70.1)	69.3(64.7-74.0)	70.5(61.2-80.0)	0.041
Peak SVG azimuth(circular SD), °	2.4(2.1-2.8)	2.4(0.9-3.9)	4.1(1.5-6.7)	6.8(3.5-10.1)	4.7(-0.5 to 9.9)	4.8(-6.6 to 16.2)	0.095
Area SVG azimuth(circular SD), °	24.5(24.1-24.9)	24.6(22.9-26.3)	23.4(20.8-26.0)	27.6(24.1-31.0)	27.2(21.6-32.8)	25.1(14.0-36.3)	0.842
SAI QRST, mV*ms	142.2(49.9)	149.5(55.9)	151.1(55.5)	146.4(50.5)	143.0(47.9)	157.8(58.1)	<0.0001
Peak SVG magnitude(SD), mV	1.60(0.44)	1.66(0.46)	1.64(0.49)	1.68(0.48)	1.66(0.41)	1.62(0.39)	0.0002
SVG magnitude, mV	1.70(0.48)	1.76(0.53)	1.74(0.52)	1.81(0.56)	1.72(0.50)	1.79(0.43)	0.003

Table 3. Association of GEH with incident stroke in Cox models.

	Predictor, per 1 SD	Model 1		Model 2		Model 3		Model 4		Model 5	
		HR(95%CI)	P-value	HR(95%CI)	P-value	HR(95%CI)	P-value	HR(95%CI)	P-value	HR(95%CI)	P-value
Embolitic stroke (n=400)	Peak QRS-T angle	1.28(1.17-1.39)#	<0.0001	1.18(1.08-1.29)#	<0.0001	1.12(1.02-1.23)	0.020	1.11(1.01-1.23)	0.034	1.12(1.02-1.23)#	0.016
	Area QRS-T angle	1.30(1.18-1.43)#	<0.0001	1.23(1.11-1.35)#	<0.0001	1.15(1.04-1.27)#	0.007	1.15(1.03-1.28)#	0.012	1.14(1.03-1.25)#	0.011
	Peak SVG elevation	1.14(1.03-1.26)#	0.011	1.07(0.97-1.19)	0.187	1.06(0.95-1.17)	0.308	1.05(0.94-1.18)	0.353	1.04(0.94-1.16)	0.450
	Area SVG elevation	1.11(1.01-1.21)#	0.037	1.04(0.95-1.15)#	0.382	1.03(0.93-1.13)	0.599	1.02(0.92-1.13)	0.676	1.02(0.92-1.13)	0.702
	Peak SVG azimuth	1.13(1.04-1.24)	0.006	1.09(0.99-1.19)	0.079	1.04(0.95-1.14)	0.407	1.03(0.94-1.14)	0.532	1.03(0.94-1.12)	0.519
	Area SVG azimuth	1.07(0.97-1.19)#	0.172	1.04(0.94-1.15)	0.446	1.00(0.91-1.11)	0.949	0.98(0.88-1.08)	0.656	1.03(0.94-1.12)	0.559
	Peak SVG magnitude	1.07(0.96-1.18)	0.220	1.05(0.95-1.17)	0.320	1.10(0.99-1.22)	0.078	1.09(0.98-1.21)	0.117	1.13(1.02-1.25)	0.018
	Area SVG magnitude	1.03(0.93-1.14)	0.559	1.05(0.94-1.17)	0.398	1.08(0.97-1.21)	0.146	1.07(0.96-1.20)	0.207	1.19(1.08-1.32)	0.001
	SAI QRST	1.17(1.07-1.28)	0.001	1.17(1.07-1.28)	<0.0001	1.15(1.05-1.27)	0.002	1.20(1.07-1.34)	0.002	1.16(1.06-1.27)	0.001
	Bazett's QTc	1.13(1.05-1.23)#	0.002	1.06(0.97-1.16)#	0.223	1.00(0.90-1.10)	0.924	0.99(0.89-1.10)#	0.850	0.99(0.90-1.09)	0.865
	QRS duration	1.05(0.95-1.16)	0.333	1.01(0.91-1.12)	0.816	1.00(0.90-1.11)	0.988	0.98(0.86-1.13)	0.811	0.94(0.83-1.08)	0.393
	PVC	2.15(1.28-3.60)	0.004	2.17(1.29-3.64)	0.003	1.72(1.02-2.91)	0.043	1.72(1.02-2.92)	0.044	1.27(0.85-1.95)	0.237
	TD-IBBB	0.91(0.29-2.83)	0.870	0.84(0.27-2.63)	0.771	0.73(0.23-2.29)	0.592	0.73(0.23-2.30)	0.596	1.51(0.37-6.12)	0.563
Thrombotic stroke (n=899)	BBB/IVCD	0.98(0.61-1.58)	0.948	0.95(0.59-1.53)	0.835	0.82(0.51-1.32)	0.412	0.76(0.43-1.33)	0.340	0.83(0.54-1.29)	0.412
	ECG-LVH	1.85(1.31-2.60)#	<0.0001	1.49(1.06-2.12)#	0.024	1.32(0.93-1.88)	0.126	1.38(0.91-2.08)	0.127	1.28(0.92-1.78)	0.146
	Peak QRS-T angle	1.16(1.10-1.24)#	<0.0001	1.04(0.98-1.11)#	0.197	1.04(0.97-1.11)#	0.265	1.01(0.94-1.08)	0.810	1.06(0.99-1.13)#	0.103
	Area QRS-T angle	1.17(1.10-1.25)#	<0.0001	1.08(1.01-1.16)#	0.021	1.08(1.01-1.15)#	0.035	1.04(0.97-1.12)	0.237	1.01(0.94-1.09)#	0.718
	Peak SVG elevation	1.01(0.94-1.08)#	0.817	0.96(0.90-1.03)	0.278	0.98(0.91-1.05)	0.498	0.95(0.88-1.02)	0.163	0.98(0.91-1.05)	0.585
	Area SVG elevation	1.02(0.96-1.09)#	0.504	0.98(0.91-1.05)	0.498	0.99(0.93-1.06)	0.762	0.97(0.91-1.04)	0.386	0.98(0.92-1.05)	0.658
	Peak SVG azimuth	1.02(0.96-1.09)#	0.510	0.96(0.90-1.02)#	0.211	0.95(0.89-1.02)	0.175	0.93(0.86-0.99)	0.034	0.96(0.90-1.02)#	0.175
	Area SVG azimuth	1.09(1.02-1.17)#	0.012	1.04(0.97-1.11)	0.227	1.03(0.97-1.11)	0.338	1.02(0.95-1.09)	0.636	0.98(0.92-1.04)	0.511
	Peak SVG magnitude	1.04(0.97-1.11)	0.253	1.05(0.98-1.12)	0.186	1.05(0.98-1.13)	0.144	1.05(0.98-1.12)	0.200	1.11(1.04-1.19)	0.002
	Area SVG magnitude	1.03(0.96-1.10)	0.446	1.05(0.98-1.12)	0.203	1.05(0.98-1.13)	0.174	1.04(0.97-1.12)	0.250	1.11(1.03-1.18)	0.004
	SAI QRST	1.09(1.02-1.16)	0.010	1.07(1.01-1.14)	0.028	1.09(1.02-1.16)	0.011	1.04(0.97-1.12)	0.267	1.08(1.01-1.15)	0.022
	Bazett's QTc	1.15(1.10-1.21)#	<0.0001	1.08(1.02-1.14)#	0.007	1.08(1.02-1.15)#	0.010	1.05(0.99-1.13)	0.115	1.08(1.01-1.15)	0.025
	QRS duration	1.09(1.02-1.16)	0.010	1.07(1.001-1.13)	0.046	1.09(1.02-1.16)	0.012	1.05(0.96-1.14)	0.295	0.98(0.89-1.08)	0.686
	PVC	1.61(1.09-2.38)	0.016	1.53(1.03-2.26)	0.034	1.48(1.00-2.20)	0.050	1.47(0.99-2.18)	0.058	0.84(0.58-1.22)	0.362
Hemorrhagic stroke (n=187)	TD-IBBB	1.02(0.51-2.05)	0.951	0.95(0.47-1.91)	0.887	0.96(0.48-1.92)	0.902	0.97(0.48-1.95)	0.930	0.55(0.14-2.22)	0.399
	BBB/IVCD	1.13(0.84-1.53)	0.415	1.11(0.82-1.50)	0.493	1.15(0.85-1.56)	0.366	0.89(0.62-1.29)	0.551	0.86(0.62-1.17)	0.334
	ECG-LVH	1.61(1.28-2.02)#	<0.0001	1.33(1.05-1.68)#	0.017	1.34(1.06-1.70)	0.014	1.20(0.91-1.57)	0.200	1.15(0.92-1.45)	0.225
	Peak QRS-T angle	1.27(1.12-1.44)#	<0.0001	1.22(1.07-1.39)	0.004	1.23(1.08-1.41)	0.002	1.24(1.08-1.42)	0.003	1.20(1.04-1.38)	0.015
	Area QRS-T angle	1.19(1.02-1.37)#	0.022	1.12(0.97-1.30)	0.135	1.15(0.99-1.33)	0.076	1.16(0.99-1.36)	0.073	1.13(0.97-1.32)	0.127
	Peak SVG elevation	0.98(0.84-1.14)	0.798	1.00(0.85-1.17)	0.959	1.00(0.85-1.18)	0.975	0.98(0.83-1.15)	0.783	1.06(0.90-1.25)	0.508
	Area SVG elevation	1.00(0.86-1.16)	0.995	1.00(0.86-1.17)	0.985	1.01(0.86-1.18)	0.910	0.98(0.84-1.15)	0.827	1.11(0.95-1.30)	0.178
	Peak SVG azimuth	1.17(1.03-1.33)	0.018	1.13(0.98-1.29)	0.084	1.13(0.99-1.29)	0.078	1.13(0.98-1.30)	0.097	1.06(0.92-1.23)	0.409
	Area SVG azimuth	1.19(1.03-1.39)	0.021	1.15(0.98-1.34)	0.082	1.15(0.98-1.34)	0.077	1.16(0.99-1.37)	0.072	1.12(0.95-1.32)	0.179
	Peak SVG magnitude	1.09(0.94-1.26)	0.244	1.03(0.89-1.20)	0.662	1.02(0.88-1.18)	0.814	1.02(0.88-1.19)	0.775	1.14(0.98-1.31)	0.084
	Area SVG magnitude	1.15(1.00-1.34)	0.052	1.07(0.92-1.25)	0.377	1.05(0.90-1.23)	0.502	1.06(0.91-1.24)	0.428	1.17(1.01-1.35)	0.040
	SAI QRST	1.13(0.99-1.30)	0.079	1.05(0.90-1.22)	0.513	1.06(0.90-1.24)	0.497	1.08(0.91-1.30)	0.369	1.23(1.06-1.43)	0.007
	Bazett's QTc	1.06(0.93-1.21)	0.373	1.02(0.89-1.18)	0.759	1.04(0.91-1.20)	0.552	1.06(0.91-1.23)	0.480	1.01(0.86-1.19)	0.883

QRS duration	0.92(0.78-1.09)	0.332	0.93(0.79-1.10)	0.387	0.94(0.79-1.11)	0.453	0.81(0.66-0.996)	0.046	0.91(0.72-1.14)	0.413
PVC	1.20(0.44-3.23)	0.721	1.11(0.41-3.00)	0.837	1.18(0.43-3.22)	0.742	1.11(0.41-3.04)	0.838	0.31(0.08-1.28)	0.105
TD-IBBB	1.84(0.59-5.76)	0.295	1.83(0.58-5.74)	0.302	1.88(0.60-5.93)	0.281	1.84(0.58-5.82)	0.297	1.24(0.16-9.43)	0.835
BBB/IVCD	1.07(0.52-2.18)	0.853	1.10(0.54-2.25)	0.786	1.16(0.57-2.37)	0.688	1.42(0.62-3.21)	0.406	0.56(0.23-1.34)	0.191
ECG-LVH	1.51(0.89-2.54)	0.123	1.33(0.78-2.27)	0.301	1.34(0.78-2.29)	0.293	1.37(0.74-2.55)	0.315	1.11(0.64-1.92)	0.711

Table 4. Association of GEH with incident stroke in Cox models with pure stroke type outcomes.

	Predictor, per 1 SD	Model 1		Model 2		Model 3		Model 4		Model 5	
		HR(95%CI)	P-value	HR(95%CI)	P-value	HR(95%CI)	P-value	HR(95%CI)	P-value	HR(95%CI)	P-value
Embolitic stroke (n=335)	Peak QRS-T angle	1.27(1.15-1.39)#	<0.0001	1.19(1.08-1.31)	0.001	1.12(1.01-1.24)	0.027	1.11(0.99-1.23)	0.067	1.10(0.99-1.22)#	0.074
	Area QRS-T angle	1.29(1.16-1.43)#	<0.0001	1.23(1.11-1.37)#	<0.0001	1.15(1.03-1.28)#	0.014	1.13(1.01-1.27)#	0.040	1.12(1.01-1.25)#	0.036
	Peak SVG elevation	1.13(1.01-1.25)#	0.031	1.07(0.95-1.20)	0.259	1.05(0.94-1.17)	0.404	1.04(0.92-1.17)	0.525	1.00(0.89-1.12)	0.956
	Area SVG elevation	1.11(1.00-1.22)	0.055	1.05(0.95-1.17)	0.348	1.03(0.93-1.15)	0.545	1.02(0.92-1.14)	0.681	1.00(0.90-1.12)	0.934
	Peak SVG azimuth	1.12(1.02-1.24)	0.019	1.08(0.98-1.19)	0.137	1.04(0.93-1.15)	0.505	1.02(0.91-1.13)	0.758	0.98(0.89-1.09)#	0.760
	Area SVG azimuth	1.04(0.93-1.16)#	0.472	1.01(0.91-1.13)	0.814	0.98(0.88-1.09)	0.693	0.94(0.84-1.05)	0.274	0.99(0.90-1.09)	0.881
	Peak SVG magnitude	1.08(0.97-1.21)	0.171	1.08(0.96-1.21)	0.179	1.13(1.01-1.27)	0.038	1.11(0.99-1.25)	0.068	1.17(1.05-1.31)	0.006
	Area SVG magnitude	1.06(0.94-1.18)	0.335	1.09(0.97-1.22)	0.167	1.13(1.00-1.27)	0.047	1.11(0.99-1.25)	0.083	1.23(1.11-1.38)	<0.0001
	SAI QRST	1.20(1.09-1.31)	<0.0001	1.21(1.10-1.33)	<0.0001	1.20(1.09-1.32)	<0.0001	1.23(1.09-1.39)	0.001	1.16(1.05-1.28)	0.003
	Bazett's QTc	1.14(1.04-1.24)#	0.004	1.07(0.97-1.18)	0.187	1.00(0.90-1.12)	0.963	0.99(0.88-1.12)	0.893	0.99(0.90-1.09)	0.865
	QRS duration	1.07(0.96-1.19)	0.215	1.03(0.92-1.15)	0.604	1.02(0.91-1.14)	0.733	0.99(0.85-1.15)	0.880	1.00(0.90-1.10)	0.948
	PVC	2.23(1.28-3.89)	0.005	2.25(1.29-3.94)	0.004	1.76(1.00-3.09)	0.050	1.73(0.98-3.06)	0.058	1.43(0.92-2.21)	0.110
	TD-IBBB	0.72(0.18-2.91)	0.648	0.69(0.17-2.77)	0.601	0.59(0.15-2.37)	0.456	0.58(0.14-2.33)	0.441	0.92(0.13-6.63)	0.938
Thrombotic stroke (n=819)	BBB/IVCD	0.96(0.57-1.62)	0.887	0.92(0.55-1.55)	0.751	0.80(0.47-1.35)	0.400	0.69(0.38-1.28)	0.240	0.74(0.46-1.19)	0.209
	ECG-LVH	2.03(1.41-2.92)#	<0.0001	1.71(1.18-2.48)#	0.004	1.52(1.04-2.22)	0.030	1.55(1.00-2.41)	0.048	1.22(0.85-1.76)	0.279
	Peak QRS-T angle	1.16(1.08-1.23)#	<0.0001	1.04(0.97-1.11)#	0.278	1.04(0.97-1.11)#	0.272	1.00(0.93-1.08)	0.925	1.04(0.97-1.11)#	0.272
	Area QRS-T angle	1.16(1.09-1.25)#	<0.0001	1.08(1.00-1.15)#	0.041	1.08(1.00-1.16)	0.043	1.04(0.96-1.12)	0.359	1.00(0.93-1.07)#	0.958
	Peak SVG elevation	0.99(0.94-1.07)#	0.866	0.95(0.88-1.02)	0.189	0.97(0.90-1.04)	0.392	0.94(0.87-1.01)	0.101	0.96(0.89-1.04)	0.310
	Area SVG elevation	1.02(0.95-1.09)#	0.608	0.98(0.91-1.05)	0.514	0.99(0.92-1.06)	0.814	0.97(0.90-1.04)	0.396	0.98(0.91-1.05)	0.539
	Peak SVG azimuth	1.01(0.94-1.08)#	0.778	0.95(0.88-1.02)#	0.127	0.95(0.88-1.02)	0.134	0.91(0.85-0.99)	0.018	0.94(0.88-1.00)#	0.068
	Area SVG azimuth	1.08(1.01-1.16)#	0.034	1.03(0.96-1.10)	0.385	1.03(0.96-1.10)	0.481	1.01(0.94-1.08)	0.883	0.97(0.91-1.03)	0.266
	Peak SVG magnitude	1.05(0.97-1.12)	0.218	1.06(0.98-1.14)	0.124	1.06(0.99-1.14)	0.096	1.06(0.98-1.14)	0.142	1.12(1.04-1.20)	0.002
	Area SVG magnitude	1.03(0.96-1.11)	0.349	1.06(0.98-1.14)	0.130	1.06(0.99-1.15)	0.109	1.05(0.98-1.14)	0.175	1.11(1.03-1.19)	0.004
	SAI QRST	1.09(1.02-1.17)	0.008	1.08(1.01-1.15)	0.020	1.10(1.03-1.18)	0.004	1.05(0.97-1.13)	0.240	1.07(1.00-1.15)	0.045
	Bazett's QTc	1.16(1.10-1.22)#	<0.0001	1.09(1.02-1.15)#	0.006	1.09(1.03-1.16)#	0.005	1.06(0.99-1.14)#	0.087	1.08(1.01-1.15)	0.030
	QRS duration	1.10(1.03-1.17)	0.004	1.08(1.01-1.15)	0.022	1.11(1.03-1.18)	0.003	1.06(0.97-1.16)	0.212	1.00(0.91-1.10)	0.995
	PVC	1.56(1.03-2.37)	0.034	1.48(0.98-2.25)	0.065	1.46(0.96-2.23)	0.076	1.43(0.94-2.19)	0.093	0.86(0.58-1.28)	0.468
Hemorrhagic stroke (n=168)	TD-IBBB	0.98(0.47-2.07)	0.960	0.92(0.44-1.94)	0.828	0.93(0.44-1.97)	0.859	0.95(0.45-2.00)	0.891	0.62(0.15-2.50)	0.500
	BBB/IVCD	1.15(0.84-1.58)	0.368	1.12(0.82-1.54)	0.466	1.19(0.87-1.62)	0.286	0.87(0.60-1.28)	0.487	0.79(0.57-1.11)	0.173
	ECG-LVH	1.65(1.30-2.09)#	<0.0001	1.39(1.09-1.77)	0.008	1.43(1.12-1.83)	0.004	1.24(0.93-1.65)	0.138	1.13(0.89-1.44)	0.303
	Peak QRS-T angle	1.25(1.09-1.44)#	0.001	1.21(1.05-1.39)	0.009	1.23(1.07-1.42)	0.004	1.24(1.07-1.44)	0.005	1.16(0.99-1.35)	0.068
	Area QRS-T angle	1.16(0.99-1.36)	0.059	1.10(0.94-1.29)	0.251	1.13(0.96-1.33)	0.129	1.14(0.96-1.36)	0.127	1.08(0.91-1.28)	0.369
	Peak SVG elevation	0.97(0.83-1.14)	0.719	1.01(0.86-1.19)	0.890	1.01(0.85-1.19)	0.933	0.98(0.83-1.17)	0.856	1.08(0.91-1.28)	0.397
	Area SVG elevation	1.00(0.85-1.17)	0.980	1.00(0.86-1.17)	0.985	1.02(0.86-1.20)	0.840	0.99(0.84-1.17)	0.933	1.11(0.94-1.31)	0.225
	Peak SVG azimuth	1.17(1.02-1.34)	0.024	1.13(0.98-1.30)	0.099	1.14(0.99-1.31)	0.077	1.14(0.98-1.32)	0.095	1.06(0.91-1.24)	0.465
	Area SVG azimuth	1.20(1.03-1.41)	0.023	1.15(0.98-1.35)	0.094	1.16(0.99-1.37)	0.074	1.17(0.99-1.39)	0.071	1.10(0.92-1.30)	0.299
	Peak SVG magnitude	1.14(0.98-1.34)	0.087	1.09(0.93-1.27)	0.288	1.07(0.91-1.25)	0.401	1.08(0.92-1.26)	0.369	1.21(1.04-1.40)	0.015
	Area SVG magnitude	1.20(1.03-1.40)	0.019	1.11(0.94-1.30)	0.209	1.09(0.93-1.28)	0.305	1.10(0.931-1.30)	0.256	1.23(1.06-1.43)	0.008
	SAI QRST	1.14(0.99-1.33)	0.072	1.06(0.90-1.24)	0.505	1.06(0.90-1.26)	0.474	1.09(0.90-1.32)	0.384	1.22(1.04-1.43)	0.016
	Bazett's QTc	1.06(0.92-1.22)	0.443	1.03(0.89-1.19)	0.705	1.06(0.91-1.23)	0.450	1.07(0.92-1.25)	0.397	1.01(0.85-1.20)	0.939

QRS duration	0.93(0.78-1.11)	0.409	0.94(0.79-1.13)	0.521	0.95(0.79-1.14)	0.586	0.83(0.66-1.03)	0.090	0.93(0.73-1.19)	0.589
PVC	1.00(0.32-3.12)	0.995	0.93(0.30-2.92)	0.902	1.03(0.33-3.27)	0.955	0.97(0.31-3.10)	0.965	0.36(0.09-1.48)	0.158
TD-IBBB	2.08(0.66-6.51)	0.210	2.12(0.67-6.67)	0.198	2.16(0.69-6.83)	0.188	2.11(0.67-6.66)	0.205	1.55(0.21-11.66)	0.670
BBB/IVCD	1.04(0.49-2.22)	0.920	1.08(0.50-2.31)	0.849	1.14(0.63-2.45)	0.736	1.32(0.55-3.18)	0.538	0.50(0.19-1.27)	0.144
ECG-LVH	1.23(0.90-1.69)	0.219	1.31(0.73-2.36)	0.368	1.33(0.73-2.40)	0.351	1.33(0.68-2.61)	0.409	1.19(0.67-2.12)	0.554

Table 5. Association of GEH with incident hemorrhagic stroke in Cox models with sequential adjustment applied to models 3-5.

	Predictor, per 1 SD	Model 1		Model 2		Model 3		Model 4		Model 5	
		HR(95%CI)	P-value	HR(95%CI)	P-value	HR(95%CI)	P-value	HR(95%CI)	P-value	HR(95%CI)	P-value
Hemorrhagic stroke (n=187)	Peak QRS-T angle	1.27(1.12-1.44)#	<0.0001	1.22(1.07-1.39)	0.004	1.27(1.12-1.44)	<0.0001	1.26(1.11-1.45)	0.001	1.24(1.07-1.42)	0.003
	Area QRS-T angle	1.19(1.02-1.37)#	0.022	1.12(0.97-1.30)	0.135	1.19(1.03-1.38)	0.019	1.19(1.02-1.39)	0.028	1.17(1.00-1.37)	0.052
	Peak SVG elevation	0.98(0.84-1.14)	0.798	1.00(0.85-1.17)	0.959	0.98(0.84-1.15)	0.806	0.95(0.81-1.11)	0.522	1.03(0.87-1.22)	0.733
	Area SVG elevation	1.00(0.86-1.16)	0.995	1.00(0.86-1.17)	0.985	1.00(0.86-1.17)	0.959	0.97(0.83-1.13)	0.702	1.09(0.94-1.28)	0.254
	Peak SVG azimuth	1.17(1.03-1.33)	0.018	1.13(0.98-1.29)	0.084	1.16(1.02-1.33)	0.025	1.16(1.01-1.34)	0.030	1.09(0.95-1.27)	0.220
	Area SVG azimuth	1.19(1.03-1.39)	0.021	1.15(0.98-1.34)	0.082	1.19(1.02-1.39)	0.026	1.20(1.03-1.41)	0.023	1.15(0.98-1.35)	0.096
	Peak SVG magnitude	1.09(0.94-1.26)	0.244	1.03(0.89-1.20)	0.662	1.08(0.93-1.25)	0.324	1.10(0.94-1.27)	0.231	1.18(1.02-1.36)	0.022
	Area SVG magnitude	1.15(1.00-1.34)	0.052	1.07(0.92-1.25)	0.377	1.14(0.99-1.32)	0.076	1.17(1.01-1.35)	0.037	1.22(1.06-1.41)	0.005
	SAI QRST	1.13(0.99-1.30)	0.079	1.05(0.90-1.22)	0.513	1.14(0.99-1.31)	0.077	1.19(1.01-1.40)	0.033	1.28(1.12-1.47)	<0.0001
	Bazett's QTc	1.06(0.93-1.21)	0.373	1.02(0.89-1.18)	0.759	1.06(0.93-1.22)	0.385	1.07(0.93-1.23)	0.348	1.05(0.90-1.23)	0.549
	QRS duration	0.92(0.78-1.09)	0.332	0.93(0.79-1.10)	0.387	0.92(0.78-1.10)	0.365	0.77(0.63-0.95)	0.013	0.88(0.70-1.11)	0.274
	PVC	1.20(0.44-3.23)	0.721	1.11(0.41-3.00)	0.837	1.22(0.45-3.31)	0.695	1.12(0.41-3.04)	0.822	0.32(0.0801-32)	0.116
	TD-IBBB	1.84(0.59-5.76)	0.295	1.83(0.58-5.74)	0.302	1.81(0.58-5.68)	0.309	1.75(0.56-5.48)	0.338	1.84(0.25-13.3)	0.547
Pure Hemorrhagic stroke (n=168)	BBB/IVCD	1.07(0.52-2.18)	0.853	1.10(0.54-2.25)	0.786	1.10(0.53-1.24)	0.804	1.31(0.58-2.95)	0.513	0.49(0.19-1.24)	0.132
	ECG-LVH	1.51(0.89-2.54)	0.123	1.33(0.78-2.27)	0.301	1.46(0.86-1.48)	0.164	1.57(0.85-2.88)	0.147	1.20(0.69-1.07)	0.514
	Peak QRS-T angle	1.25(1.09-1.44)#	0.001	1.21(1.05-1.39)	0.009	1.27(1.10-1.45)	0.001	1.26(1.09-1.45)	0.002	1.19(1.02-1.39)	0.026
	Area QRS-T angle	1.16(0.99-1.36)	0.059	1.10(0.94-1.29)	0.251	1.18(1.01-1.38)	0.037	1.19(0.99-1.39)	0.065	1.12(0.94-1.32)	0.199
	Peak SVG elevation	0.97(0.83-1.14)	0.719	1.01(0.86-1.19)	0.890	0.97(0.82-1.15)	0.734	0.94(0.80-1.12)	0.503	1.05(0.88-1.25)	0.610
	Area SVG elevation	1.00(0.85-1.17)	0.980	1.00(0.86-1.17)	0.985	1.00(0.86-1.18)	0.970	0.97(0.83-1.14)	0.746	1.09(0.92-1.28)	0.320
	Peak SVG azimuth	1.17(1.02-1.34)	0.024	1.13(0.98-1.30)	0.099	1.18(1.02-1.35)	0.023	1.17(1.01-1.35)	0.035	1.09(0.94-1.27)	0.262
	Area SVG azimuth	1.20(1.03-1.41)	0.023	1.15(0.98-1.35)	0.094	1.21(1.03-1.42)	0.022	1.21(1.03-1.44)	0.025	1.13(0.95-1.34)	0.172
	Peak SVG magnitude	1.14(0.98-1.34)	0.087	1.09(0.93-1.27)	0.288	1.13(0.97-1.32)	0.122	1.15(0.98-1.35)	0.078	1.26(1.08-1.46)	0.003
	Area SVG magnitude	1.20(1.03-1.40)	0.019	1.11(0.94-1.30)	0.209	1.19(1.02-1.39)	0.028	1.22(1.04-1.42)	0.013	1.30(1.12-1.50)	<0.0001
	SAI QRST	1.14(0.99-1.33)	0.072	1.06(0.90-1.24)	0.505	1.15(0.99-1.34)	0.066	1.21(1.02-1.43)	0.030	1.28(1.10-1.47)	0.001
	Bazett's QTc	1.06(0.92-1.22)	0.443	1.03(0.89-1.19)	0.705	1.07(0.92-1.24)	0.369	1.07(0.92-1.24)	0.400	1.04(0.88-1.23)	0.661
	QRS duration	0.93(0.78-1.11)	0.409	0.94(0.79-1.13)	0.521	0.93(0.78-1.11)	0.441	0.79(0.64-0.98)	0.034	0.90(0.71-1.15)	0.397
	PVC	1.00(0.32-3.12)	0.995	0.93(0.30-2.92)	0.902	1.05(0.33-3.31)	0.933	0.93(0.30-2.93)	0.904	0.38(0.09-1.53)	0.173
	TD-IBBB	2.08(0.66-6.51)	0.210	2.12(0.67-6.67)	0.198	2.05(0.65-6.46)	0.218	1.97(0.63-6.18)	0.246	1.84(0.25-13.33)	0.547
	BBB/IVCD	1.04(0.49-2.22)	0.920	1.08(0.50-2.31)	0.849	1.07(0.50-2.31)	0.854	1.23(0.52-2.94)	0.635	0.49(0.19-1.24)	0.132
	ECG-LVH	1.23(0.90-1.69)	0.219	1.31(0.73-2.36)	0.368	1.41(0.79-2.53)	0.246	1.47(0.75-2.86)	0.259	1.27(0.71-2.25)	0.423

Models 1 and 2 are the same as reported in Table 3.

Figure legends

Figure 1. Flowchart of study cohort development.

Figure 2. Adjusted Cox proportional hazard ratio (HR) with 95% confidence interval (CI) for the association of peak and area QRS-T angle, SAI QRST, and a PVC on a 10-second ECG with EBI. Model 1 (green diamond) was adjusted for age, sex, and race-study center group. Model 2 (orange triangle) in addition to model 1 covariates included BMI, WHR, total cholesterol, HDL, triglyceride level, use of lipid-lowering medications, current smoking, consumption of alcohol, level of physical activity at leisure time, diabetes, hypertension, levels of systolic and diastolic blood pressure, use of blood pressure-lowering drugs, eGFR_{CKD-EPI}, and the presence of carotid artery plaque. Model 3 (blue oval) in addition to model 2 covariates included abnormal P wave indices (P axis, PR interval, PTF_{V1}), heart rate, use of antiarrhythmic drugs, anticoagulants, and aspirin, the presence of PACs, S or V median beat at any visit and AF at baseline or at any time during follow-up. Model 4 (red rectangle) adjusted for model 3 covariates plus QRS duration, QTc interval, presence of BBB/IVCD, ECG-LVH, categorical GEH risk score, and the presence of PVCs. Time-updated model 5 (cyan X) included all model 4 covariates with the following ECG variables that were updated at the date of ECG recording in visits 1-5: QRS duration, QTc interval, presence of BBB/IVCD, ECG-LVH, GEH variables, abnormal P-axis, PTF_{V1} and PR interval, heart rate, presence of PAC and PVC on a single 10-second 12-lead ECG, and a type of median beat. Black lines correspond to 95% CI bounds.

Figure 3. Adjusted (model 1) risk of cardioembolic brain infarction associated with area QRS-T angle (A) and SAI QRST (B). Restricted cubic spline with 95% CI shows a change in the hazard ratio (Y-axis) in response to QRS-T angle (A) and SAI QRST (B) change (X-axis). 50th

percentile of QRS-T angle (A) and SAI QRST (B) is selected as a reference. Knots of area QRS-T angle are at 21 – 48 – 69 – 114 degrees. Knots of SAI QRST are at 83 – 119 – 151 – 230 mV*ms.

Figure 4. Adjusted (model 1) risk of thrombotic brain infarction associated with area QRS-T angle (A) and SAI QRST (B). See Figure 3 legend for the details.

Figure 5. Adjusted Cox proportional hazard ratio (HR) with 95% confidence interval (CI) for the association of peak and area QRS-T angle, SAI QRST, and a PVC on a 10-second ECG with TBI. See Figure 2 legend for the details.

Figure 6. Adjusted (model 1) risk of hemorrhagic stroke associated with area QRS-T angle (A) and SAI QRST (B). See Figure 3 legend for the details.

Figure 7. Adjusted Cox proportional hazard ratio (HR) with 95% confidence interval (CI) for the association of peak and area QRS-T angle, SAI QRST, and a TD-IBBB on a 10-second ECG with ICH. See Figure 2 legend for the details. Association of TD-IBBB with pure incident hemorrhagic stroke in Cox models with the sequential adjustment is reported.

Figure 8. Time-updated adjusted risk of (A) cardioembolic, (B) thrombotic brain infarction, and (C) intracranial hemorrhage associated with SVG magnitude. Time-updated Cox regression models were adjusted for age, sex, race and study center, time-updated heart rate, and the type of median beat. Restricted cubic spline with 95% CI shows a change in the hazard ratio (Y-axis) in response to SVG magnitude change (X-axis). The 50th percentile of SVG magnitude is selected as a reference. Knots of SVG magnitude are at 0.92 – 1.43 – 1.79 – 2.51 mV.

Figure 9. Adjusted Cox proportional hazard ratio (HR) with 95% confidence interval (CI) for the association of SVG magnitude with EBI (green diamond), TBI (red triangle), and ICH (blue circle) in time-updated model 5. See Figure 2 legend for the details.

Figure 10. Mechanisms of ischemic stroke. Red color highlights the mechanisms suggested by this study.

Figure 11. Mechanisms of hemorrhagic stroke. Red color highlights the mechanisms proposed by this study.

Figure 1:

Figure 2:

Figure 3:

Figure 4:

Figure 5:

Figure 6:

Figure 7:

Figure 8:

Figure 9:

Figure 10:

Figure 11:

Mechanisms of hemorrhagic stroke

Supplemental Figure 1 A. Representative example of tachycardia-dependent intermittent right bundle branch block on a 12-lead ECG (A) and orthogonal XYZ ECG (B). Normal sinus beats are labeled N. Sinus beats with intermittent bundle branch block beats are labeled I.

Supplemental Figure 2. A representative example of an aberrant premature atrial complex on a 12-lead ECG (A) and orthogonal XYZ ECG (B). Normal sinus beats are labeled N. Premature atrial complexes with normal ventricular conduction are labeled A. Premature atrial complex with aberrant ventricular conduction (right bundle branch block) is labeled W.